CD2	B-protein
signalling	O
induces	O
phosphorylation	O
of	O
CREB	B-protein
in	O
primary	B-cell_type
lymphocytes	I-cell_type
.	O

Promoter	O
sequences	O
responsive	O
to	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
are	O
found	O
in	O
a	O
number	O
of	O
cellular	B-DNA
genes	I-DNA
,	O
and	O
bind	O
transcription	B-protein
factors	I-protein
of	O
the	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	I-protein
/activating	I-protein
transcription	I-protein
factor-1	I-protein
(	I-protein
ATF-1	I-protein
)	I-protein
family	I-protein
.	O

We	O
have	O
used	O
a	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
model	O
of	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
transcription	O
to	O
investigate	O
the	O
influence	O
of	O
lymphocyte	O
activation	O
on	O
transcription	O
from	O
homologous	O
regions	O
in	O
the	O
viral	B-DNA
promoter	I-DNA
.	O

We	O
previously	O
demonstrated	O
increased	O
HTLV-1	O
transcription	O
following	O
CD2	O
but	O
not	O
CD3	O
receptor	O
cross-linking	O
.	O

We	O
hypothesized	O
that	O
this	O
increased	O
viral	O
transcription	O
was	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
phosphorylation	O
of	O
CREB	B-protein
.	O

Therefore	O
,	O
we	O
investigated	O
CD2	B-protein
and	O
CD3	B-protein
receptor	I-protein
-mediated	O
signalling	O
in	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

CD2	B-protein
,	O
but	O
not	O
CD3	B-protein
,	O
cross-linking	O
increased	O
cAMP	O
detected	O
by	O
competitive	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
approximately	O
fourfold	O
.	O

CD2	B-protein
cross-linking	O
concurrently	O
increased	O
phosphorylation	O
of	O
CREB	B-protein
detected	O
by	O
immunoblot	O
assay	O
eightfold	O
.	O

Consistent	O
with	O
post-translational	O
regulation	O
,	O
no	O
change	O
in	O
total	O
level	O
of	O
CREB	B-protein
protein	O
was	O
observed	O
.	O

Phosphorylation	O
of	O
CREB	B-protein
occurred	O
through	O
a	O
herbimycin	O
A	O
and	O
Rp-cAMP-	O
sensitive	O
pathway	O
,	O
suggesting	O
phosphorylation	O
required	O
antecedent	O
activation	O
of	O
both	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
(	O
PTK	B-protein
)	O
and	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
.	O

Both	O
CD2	B-protein
and	O
CD3	B-protein
cross-linking	O
increased	O
binding	O
of	O
nuclear	B-protein
proteins	I-protein
to	O
a	O
radiolabelled	O
CRE	O
oligonucleotide	O
probe	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggesting	O
that	O
lymphocyte	O
activation	O
enhances	O
binding	O
independently	O
of	O
phosphorylation	O
of	O
CREB	B-protein
at	O
serine	O
133	O
.	O

These	O
data	O
indicate	O
specific	O
modulation	O
of	O
the	O
CREB/ATF-1	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
by	O
the	O
CD2	B-protein
signalling	O
pathway	O
and	O
suggest	O
CD2	B-protein
receptor	O
modulation	O
of	O
CRE	B-DNA
-mediated	O
transcription	O
following	O
ligand	O
engagement	O
(	O
e.g.	O
cell-to-cell	O
contact	O
)	O
.	O

Immunology	NULL
1998	NULL
95	NULL
544-552	NULL
CD2	NULL
signalling	NULL
induces	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
in	NULL
primary	NULL
lymphocytes	NULL
D.	NULL
J.	NULL
GUYOT	NULL
,	NULL
*	NULL
G.	NULL
C.	NULL
NEWBOUND*	NULL
&	NULL
M.	NULL
D.	NULL
LAIRMORE*t	NULL
*Center	NULL
for	NULL
Retrovirus	NULL
Research	NULL
and	NULL
Department	NULL
of	NULL
Veterinary	NULL
Biosciences	NULL
,	NULL
College	NULL
of	NULL
Veterinary	NULL
Medicine	NULL
and	NULL
tComprehensive	NULL
Cancer	NULL
Center	NULL
,	NULL
The	NULL
Arthur	NULL
James	NULL
Cancer	NULL
Hospital	NULL
and	NULL
Research	NULL
Institute	NULL
The	NULL
Ohio	NULL
State	NULL
University	NULL
,	NULL
Columbus	NULL
Ohio	NULL
,	NULL
USA	NULL
SUMMARY	NULL
Promoter	NULL
sequences	NULL
responsive	NULL
to	NULL
cyclic	NULL
AMP	NULL
(	NULL
cAMP	NULL
)	NULL
are	NULL
found	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cellular	NULL
genes	NULL
,	NULL
and	NULL
bind	NULL
transcription	NULL
factors	NULL
of	NULL
the	NULL
cAMP	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
/activating	NULL
transcription	NULL
factor-1	NULL
(	NULL
ATF-1	NULL
)	NULL
family	NULL
.	NULL

We	NULL
have	NULL
used	NULL
a	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
model	NULL
of	NULL
cAMP	NULL
response	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
transcription	NULL
to	NULL
investigate	NULL
the	NULL
influence	NULL
of	NULL
lymphocyte	NULL
activation	NULL
on	NULL
transcription	NULL
from	NULL
homologous	NULL
regions	NULL
in	NULL
the	NULL
viral	NULL
promoter	NULL
.	NULL

We	NULL
previously	NULL
demonstrated	NULL
increased	NULL
HTLV-1	NULL
transcription	NULL
following	NULL
CD2	NULL
but	NULL
not	NULL
CD3	NULL
receptor	NULL
cross-linking	NULL
.	NULL

We	NULL
hypothesized	NULL
that	NULL
this	NULL
increased	NULL
viral	NULL
transcription	NULL
was	NULL
mediated	NULL
,	NULL
in	NULL
part	NULL
,	NULL
through	NULL
the	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
investigated	NULL
CD2	NULL
and	NULL
CD3	NULL
receptor-mediated	NULL
signalling	NULL
in	NULL
primary	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
.	NULL

CD2	NULL
,	NULL
but	NULL
not	NULL
CD3	NULL
,	NULL
cross-linking	NULL
increased	NULL
cAMP	NULL
detected	NULL
by	NULL
competitive	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
approximately	NULL
fourfold	NULL
.	NULL

CD2	NULL
cross-linking	NULL
concurrently	NULL
increased	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
detected	NULL
by	NULL
immunoblot	NULL
assay	NULL
eightfold	NULL
.	NULL

Consistent	NULL
with	NULL
post-translational	NULL
regulation	NULL
,	NULL
no	NULL
change	NULL
in	NULL
total	NULL
level	NULL
of	NULL
CREB	NULL
protein	NULL
was	NULL
observed	NULL
.	NULL

Phosphorylation	NULL
of	NULL
CREB	NULL
occurred	NULL
through	NULL
a	NULL
herbimycin	NULL
A	NULL
and	NULL
Rp-cAMP-sensitive	NULL
pathway	NULL
,	NULL
suggesting	NULL
phosphorylation	NULL
required	NULL
antecedent	NULL
activation	NULL
of	NULL
both	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
(	NULL
PTK	NULL
)	NULL
and	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
.	NULL

Both	NULL
CD2	NULL
and	NULL
CD3	NULL
cross-linking	NULL
increased	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
a	NULL
radiolabelled	NULL
CRE	NULL
oligonucleotide	NULL
probe	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
suggesting	NULL
that	NULL
lymphocyte	NULL
activation	NULL
enhances	NULL
binding	NULL
independently	NULL
of	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
specific	NULL
modulation	NULL
of	NULL
the	NULL
CREB/ATF-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
by	NULL
the	NULL
CD2	NULL
signalling	NULL
pathway	NULL
and	NULL
suggest	NULL
CD2	NULL
receptor	NULL
modulation	NULL
of	NULL
CRE-mediated	NULL
transcription	NULL
following	NULL
ligand	NULL
engagement	NULL
(	NULL
e.g	NULL
.	NULL

cell-to-cell	NULL
contact	NULL
)	NULL
.	NULL

INTRODUCTION	NULL
Cyclic	NULL
AMP-responsive	NULL
promoter	NULL
sequences	NULL
modulate	NULL
transcription	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
cellular	NULL
genes	NULL
,	NULL
of	NULL
which	NULL
the	NULL
best	NULL
characterized	NULL
cAMP	NULL
responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
is	NULL
the	NULL
8	NULL
base	NULL
pair	NULL
palindromic	NULL
sequence	NULL
,	NULL
5-TGACGTCA-3	NULL
'	NULL
.	NULL
'	NULL

Transcription	NULL
factors	NULL
binding	NULL
this	NULL
motif	NULL
include	NULL
members	NULL
of	NULL
the	NULL
cAMP	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
and	NULL
activation	NULL
transcription	NULL
factor	NULL
(	NULL
ATF	NULL
)	NULL
family	NULL
of	NULL
leucine	NULL
zipper	NULL
proteins	NULL
.	NULL

These	NULL
proteins	NULL
are	NULL
regulated	NULL
post-transcriptionally	NULL
through	NULL
Received	NULL
23	NULL
June	NULL
1998	NULL
;	NULL
revised	NULL
1	NULL
August	NULL
1998	NULL
;	NULL
accepted	NULL
4	NULL
August	NULL
1998	NULL
.	NULL

Abbreviations	NULL
:	NULL
CRE	NULL
,	NULL
cAMP	NULL
response	NULL
element	NULL
;	NULL
CREB	NULL
,	NULL
cAMP	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
;	NULL
P-CREB	NULL
,	NULL
phosphorylated	NULL
cAMP	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
;	NULL
ATF	NULL
,	NULL
activation	NULL
transcription	NULL
factor	NULL
;	NULL
CBP	NULL
,	NULL
CREB	NULL
binding	NULL
protein	NULL
;	NULL
HTLV-1	NULL
,	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
;	NULL
TRE	NULL
,	NULL
tax-responsive	NULL
element	NULL
;	NULL
PKA	NULL
,	NULL
protein	NULL
kinase	NULL
A	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
PTK	NULL
,	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
;	NULL
Cam	NULL
,	NULL
calcium/	NULL
calmodulin	NULL
dependent	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
pri	NULL
,	NULL
prolactin	NULL
.	NULL

Correspondence	NULL
:	NULL
Dr	NULL
Michael	NULL
D.	NULL
Lairmore	NULL
,	NULL
Department	NULL
of	NULL
Veterinary	NULL
Biosciences	NULL
,	NULL
The	NULL
Ohio	NULL
State	NULL
University	NULL
,	NULL
1925	NULL
Coffey	NULL
Rd	NULL
.	NULL

Columbus	NULL
,	NULL
Ohio	NULL
,	NULL
USA	NULL
.	NULL

phosphorylation	NULL
,	NULL
in	NULL
particular	NULL
by	NULL
the	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
,	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
(	NULL
reviewed	NULL
by	NULL
Montminy	NULL
'	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
the	NULL
CRE	NULL
binding	NULL
protein	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
is	NULL
considered	NULL
a	NULL
prerequisite	NULL
for	NULL
transcription	NULL
from	NULL
CRE	NULL
promoters	NULL
.	NULL

Phosphorylated	NULL
CREB	NULL
(	NULL
P-CREB	NULL
)	NULL
is	NULL
postulated	NULL
to	NULL
recruit	NULL
the	NULL
transcriptional	NULL
coactivator/CREB	NULL
binding	NULL
protein	NULL
,	NULL
CBP	NULL
,	NULL
which	NULL
interacts	NULL
with	NULL
members	NULL
of	NULL
the	NULL
transcriptional	NULL
complex	NULL
including	NULL
RNA	NULL
polymerase	NULL
II	NULL
,	NULL
TFIIB	NULL
and	NULL
TFIID	NULL
to	NULL
initiate	NULL
transcription	NULL
.	NULL
``	NULL

We	NULL
have	NULL
used	NULL
the	NULL
human	NULL
T-cell	NULL
leukaemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
model	NULL
of	NULL
CRE-mediated	NULL
transcription	NULL
to	NULL
investigate	NULL
the	NULL
influence	NULL
of	NULL
lymphocyte	NULL
activation	NULL
on	NULL
the	NULL
viral	NULL
promoter	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL
``	NULL

The	NULL
HTLV-1	NULL
promoter/enhancer	NULL
contains	NULL
three	NULL
imperfect	NULL
21	NULL
base	NULL
pair	NULL
repeats	NULL
responsive	NULL
to	NULL
transactiv-ation	NULL
by	NULL
the	NULL
viral	NULL
encoded	NULL
40	NULL
kDa	NULL
protein	NULL
,	NULL
Tax	NULL
(	NULL
reviewed	NULL
by	NULL
Franchini	NULL
'	NULL
)	NULL
.	NULL

These	NULL
tax	NULL
responsive	NULL
elements	NULL
(	NULL
TRE	NULL
)	NULL
each	NULL
contain	NULL
three	NULL
domains	NULL
of	NULL
which	NULL
the	NULL
central	NULL
B	NULL
domain	NULL
(	NULL
5-TGACG-3	NULL
``	NULL
)	NULL
is	NULL
homologous	NULL
to	NULL
cellular	NULL
CRE	NULL
sites	NULL
and	NULL
binds	NULL
the	NULL
CREB/	NULL
ATF	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Tax	NULL
differentially	NULL
activates	NULL
the	NULL
HTLV-1	NULL
TRE	NULL
and	NULL
cellular	NULL
CRE	NULL
sites	NULL
.	NULL

Unlike	NULL
CRE	NULL
transcription	NULL
,	NULL
in	NULL
vitro	NULL
transcription	NULL
through	NULL
TRE	NULL
sites	NULL
is	NULL
not	NULL
strictly	NULL
dependent	NULL
on	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

*	NULL
``	NULL
However	NULL
,	NULL
cAMP	NULL
©1998	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
CD2	NULL
signalling	NULL
induces	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
545	NULL
augments	NULL
Tax-dependent	NULL
transcription	NULL
suggesting	NULL
that	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
in	NULL
vivo	NULL
may	NULL
enhance	NULL
transcription	NULL
from	NULL
TRE	NULL
sites	NULL
.	NULL
``	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
increased	NULL
viral	NULL
transcription	NULL
following	NULL
CD2	NULL
but	NULL
not	NULL
CD3	NULL
stimulation	NULL
of	NULL
immortalized	NULL
lymphocyte	NULL
cell	NULL
lines	NULL
infected	NULL
with	NULL
HTLV-1	NULL
and	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
transiently	NULL
cotransfected	NULL
with	NULL
the	NULL
HTLV-1	NULL
promoter	NULL
and	NULL
trans-activating	NULL
protein	NULL
Tax	NULL
.	NULL

*	NULL
As	NULL
anticipated	NULL
,	NULL
significant	NULL
levels	NULL
of	NULL
viral	NULL
transcription	NULL
required	NULL
expression	NULL
of	NULL
the	NULL
CRE-homolo-gous	NULL
TRE	NULL
sites	NULL
.	NULL

Since	NULL
these	NULL
sites	NULL
bind	NULL
the	NULL
CREB/ATF	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
and	NULL
CD2	NULL
signalling	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
induce	NULL
cAMP	NULL
,	NULL
°	NULL
we	NULL
hypothesized	NULL
the	NULL
increase	NULL
in	NULL
transcription	NULL
we	NULL
observed	NULL
was	NULL
mediated	NULL
through	NULL
the	NULL
cAMP/P-CREB	NULL
signalling	NULL
pathway	NULL
.	NULL

The	NULL
role	NULL
of	NULL
cAMP	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
is	NULL
only	NULL
partly	NULL
understood	NULL
.	NULL

By	NULL
decreasing	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
production	NULL
cAMP	NULL
blocks	NULL
cell	NULL
cycle	NULL
progression	NULL
and	NULL
inhibits	NULL
cell	NULL
proliferation	NULL
.	NULL
``	NULL

Cyclic	NULL
AMP	NULL
inhibits	NULL
Jnk	NULL
kinases	NULL
in	NULL
lympho-cytes	NULL
``	NULL
and	NULL
induces	NULL
the	NULL
inducible	NULL
cAMP	NULL
repressor	NULL
ICER	NULL
,	NULL
which	NULL
inhibits	NULL
calcineurin-mediated	NULL
expression	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL
``	NULL

None	NULL
the	NULL
less	NULL
,	NULL
cAMP	NULL
is	NULL
induced	NULL
in	NULL
lymphocytes	NULL
following	NULL
mitogen	NULL
,	NULL
CD2	NULL
and	NULL
CD3	NULL
receptor	NULL
stimulation	NULL
,	NULL
suggesting	NULL
a	NULL
positive	NULL
or	NULL
at	NULL
least	NULL
a	NULL
regulatory	NULL
role	NULL
for	NULL
cAMP	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

'*~*	NULL
'	NULL
Interactions	NULL
of	NULL
the	NULL
cAMP	NULL
and	NULL
CD3	NULL
activation	NULL
pathways	NULL
are	NULL
partly	NULL
defined	NULL
.	NULL

CD3	NULL
cross-linking	NULL
induces	NULL
cAMP	NULL
and	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
CRE	NULL
sites	NULL
in	NULL
murine	NULL
splenic	NULL
T	NULL
cells	NULL
entering	NULL
late	NULL
G1	NULL
or	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
Jurkat	NULL
cells	NULL
following	NULL
CD3	NULL
cross-linking	NULL
.	NULL

'*	NULL
These	NULL
events	NULL
are	NULL
postulated	NULL
to	NULL
occur	NULL
through	NULL
a	NULL
receptor-associated	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
pathway	NULL
with	NULL
activation	NULL
of	NULL
PLCy1	NULL
and	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
preceding	NULL
activation	NULL
of	NULL
PKA	NULL
.	NULL
``	NULL

Less	NULL
is	NULL
known	NULL
about	NULL
cAMP	NULL
signalling	NULL
following	NULL
perturbation	NULL
of	NULL
the	NULL
CD2	NULL
receptor	NULL
.	NULL

While	NULL
CD2	NULL
signalling	NULL
occurs	NULL
primarily	NULL
through	NULL
the	NULL
CD3	NULL
&	NULL
chain	NULL
,	NULL
``	NULL
differences	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
Ca**	NULL
kinetics	NULL
have	NULL
been	NULL
demonstrated	NULL
following	NULL
CD2	NULL
and	NULL
CD3	NULL
receptor	NULL
cross-linking	NULL
.	NULL

****	NULL
We	NULL
postulated	NULL
that	NULL
similar	NULL
differences	NULL
may	NULL
exist	NULL
in	NULL
the	NULL
cAMP	NULL
signalling	NULL
pathway	NULL
,	NULL
to	NULL
account	NULL
for	NULL
the	NULL
differential	NULL
transcriptional	NULL
activation	NULL
we	NULL
observed	NULL
in	NULL
the	NULL
HTLV-1	NULL
system	NULL
.	NULL

We	NULL
therefore	NULL
evaluated	NULL
the	NULL
effects	NULL
of	NULL
CD2	NULL
and	NULL
CD3	NULL
receptor	NULL
cross-linking	NULL
on	NULL
cAMP	NULL
signalling	NULL
and	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
in	NULL
primary	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
.	NULL

Our	NULL
studies	NULL
confirm	NULL
that	NULL
CD2	NULL
cross-linking	NULL
induces	NULL
cAMP	NULL
in	NULL
primary	NULL
human	NULL
PBMC	NULL
and	NULL
demonstrate	NULL
a	NULL
temporally	NULL
associated	NULL
increase	NULL
in	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
and	NULL
ATF-1	NULL
without	NULL
a	NULL
concomitant	NULL
increase	NULL
in	NULL
level	NULL
of	NULL
CREB	NULL
protein	NULL
.	NULL

Phosphorylation	NULL
of	NULL
CREB	NULL
occurred	NULL
through	NULL
an	NULL
herbimycin	NULL
A	NULL
sensitive	NULL
pathway	NULL
,	NULL
suggesting	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
cAMP	NULL
signalling	NULL
cascade	NULL
is	NULL
initiated	NULL
upon	NULL
activation	NULL
of	NULL
receptor-associated	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Consistent	NULL
with	NULL
phosphorylation	NULL
by	NULL
the	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
,	NULL
PKA	NULL
,	NULL
Rp-cAMP	NULL
reduced	NULL
the	NULL
level	NULL
of	NULL
P-CREB	NULL
~33	NULL
%	NULL
.	NULL

Inhibitors	NULL
of	NULL
other	NULL
protein	NULL
kinases	NULL
demonstrated	NULL
to	NULL
phosphorylate	NULL
CREB	NULL
in	NULL
vitro	NULL
,	NULL
including	NULL
the	NULL
PKC	NULL
inhibitor	NULL
calphostin	NULL
C	NULL
and	NULL
the	NULL
calcium/	NULL
calmodulin	NULL
(	NULL
CaM	NULL
)	NULL
kinase	NULL
inhibitor	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
CD2-mediated	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

Lymphocyte	NULL
activation	NULL
through	NULL
both	NULL
the	NULL
CD2	NULL
and	NULL
CD3	NULL
receptors	NULL
increased	NULL
binding	NULL
of	NULL
CREB	NULL
protein	NULL
to	NULL
a	NULL
specific	NULL
P-radiolabelled	NULL
CRE	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
suggesting	NULL
that	NULL
fac-	NULL
©1998	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
95	NULL
,	NULL
544-552	NULL
tors	NULL
other	NULL
than	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
enhance	NULL
DNA	NULL
binding	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
studies	NULL
indicate	NULL
that	NULL
CD2-mediated	NULL
lymphocyte	NULL
activation	NULL
induces	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
,	NULL
and	NULL
that	NULL
this	NULL
occurs	NULL
at	NULL
least	NULL
,	NULL
in	NULL
part	NULL
,	NULL
through	NULL
a	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
(	NULL
PTK	NULL
)	NULL
and	NULL
PKA	NULL
dependent	NULL
pathway	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
specific	NULL
modulation	NULL
of	NULL
the	NULL
CREB/ATF-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
by	NULL
the	NULL
CD2	NULL
signalling	NULL
pathway	NULL
and	NULL
suggest	NULL
that	NULL
the	NULL
CD2	NULL
receptor	NULL
may	NULL
have	NULL
important	NULL
implications	NULL
for	NULL
both	NULL
TRE	NULL
and	NULL
CRE-mediated	NULL
transcription	NULL
following	NULL
cell-cell	NULL
contact	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
PBMC	NULL
PBMC	NULL
were	NULL
obtained	NULL
by	NULL
leukophoresis	NULL
from	NULL
HTLV-1-negative	NULL
donors	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
PBMC	NULL
were	NULL
obtained	NULL
from	NULL
elutriated	NULL
cell	NULL
packs	NULL
by	NULL
Ficoll-Hypaque	NULL
separation	NULL
and	NULL
stored	NULL
as	NULL
frozen	NULL
aliquots	NULL
in	NULL
liquid	NULL
nitrogen	NULL
using	NULL
standard	NULL
techniques	NULL
.	NULL

Cells	NULL
were	NULL
removed	NULL
from	NULL
liquid	NULL
nitrogen	NULL
,	NULL
checked	NULL
for	NULL
viability	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
and	NULL
placed	NULL
in	NULL
RPMI-1640	NULL
media	NULL
supplemented	NULL
with	NULL
0-3	NULL
mg/ml	NULL
L-glutamine	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
,	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
,	NULL
and	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
(	NULL
complete	NULL
RPMI-1640	NULL
)	NULL
.	NULL

After	NULL
a	NULL
48-hr	NULL
rest	NULL
in	NULL
culture	NULL
,	NULL
cells	NULL
were	NULL
centrifuged	NULL
,	NULL
resuspended	NULL
at	NULL
1	NULL
x	NULL
10°	NULL
cells/ml	NULL
in	NULL
fresh	NULL
medium	NULL
and	NULL
placed	NULL
in	NULL
receptor	NULL
stimulation	NULL
protocols	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
exogenously	NULL
added	NULL
IL-2	NULL
to	NULL
avoid	NULL
costimulatory	NULL
effects	NULL
of	NULL
the	NULL
IL-2	NULL
pathway	NULL
.	NULL

PBMC	NULL
viability	NULL
after	NULL
thawing	NULL
and	NULL
receptor-mediated	NULL
stimulation	NULL
experiments	NULL
were	NULL
routinely	NULL
90	NULL
%	NULL
or	NULL
greater	NULL
in	NULL
viability	NULL
.	NULL

Receptor	NULL
cross-linking	NULL
Receptor	NULL
cross-linking	NULL
was	NULL
performed	NULL
-	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
optimal	NULL
concentrations	NULL
of	NULL
anti-CD3	NULL
and	NULL
anti-CD2	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
mAbs	NULL
)	NULL
were	NULL
determined	NULL
in	NULL
preliminary	NULL
experiments	NULL
as	NULL
assessed	NULL
by	NULL
[	NULL
PH	NULL
]	NULL
thymidine	NULL
incor-poration	NULL
.	NULL

Immobilized	NULL
anti-CD3	NULL
mAb	NULL
was	NULL
plated	NULL
into	NULL
wells	NULL
of	NULL
6-	NULL
,	NULL
24-	NULL
or	NULL
96-well	NULL
plates	NULL
by	NULL
incubating	NULL
a	NULL
1:200	NULL
dilution	NULL
of	NULL
mAb	NULL
in	NULL
nonsupplemented	NULL
RPMI-1640	NULL
media	NULL
for	NULL
1	NULL
hr	NULL
at	NULL
37°	NULL
(	NULL
OKT3	NULL
,	NULL
0-625	NULL
mg/ml	NULL
final	NULL
concentration	NULL
,	NULL
Ortho	NULL
Diagnostic	NULL
Systems	NULL
Inc.	NULL
Rariton	NULL
,	NULL
NJ	NULL
.	NULL
)	NULL

.	NULL

The	NULL
anti-CD2	NULL
mAbs	NULL
39C1.5	NULL
and	NULL
6F10.3	NULL
(	NULL
Tll.1	NULL
and	NULL
T1ll.2	NULL
epitopes	NULL
,	NULL
respectively	NULL
,	NULL
AMAC	NULL
,	NULL
Inc	NULL
,	NULL
Westbrook	NULL
,	NULL
ME	NULL
)	NULL
,	NULL
were	NULL
used	NULL
paired	NULL
in	NULL
soluble	NULL
form	NULL
at	NULL
2:5	NULL
mg/ml	NULL
in	NULL
RPMI	NULL
.	NULL

A	NULL
mouse	NULL
mAb	NULL
to	NULL
bovine	NULL
prolactin	NULL
(	NULL
pri	NULL
)	NULL
served	NULL
as	NULL
a	NULL
non-binding	NULL
control	NULL
(	NULL
2:5	NULL
mg/ml	NULL
,	NULL
courtesy	NULL
of	NULL
Dr	NULL
Charles	NULL
Brooks	NULL
,	NULL
The	NULL
Ohio	NULL
State	NULL
University	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
exogenously	NULL
added	NULL
IL-2	NULL
to	NULL
avoid	NULL
costimulatory	NULL
effects	NULL
of	NULL
the	NULL
IL-2	NULL
pathway	NULL
.	NULL

To	NULL
verify	NULL
effectiveness	NULL
of	NULL
receptor	NULL
cross-linking	NULL
and	NULL
inhibition	NULL
protocols	NULL
,	NULL
cell	NULL
proliferation	NULL
was	NULL
assessed	NULL
in	NULL
each	NULL
experiment	NULL
by	NULL
determining	NULL
[	NULL
PH	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
PBMC	NULL
after	NULL
72	NULL
hr	NULL
in	NULL
culture	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

``	NULL
*	NULL
Results	NULL
are	NULL
expressed	NULL
both	NULL
as	NULL
mean	NULL
c.p.m	NULL
.	NULL

+SD	NULL
of	NULL
triplicate	NULL
samples	NULL
,	NULL
and	NULL
as	NULL
stimulation	NULL
indices	NULL
presenting	NULL
the	NULL
percentage	NULL
of	NULL
[	NULL
BH	NULL
incorporation	NULL
measured	NULL
in	NULL
stimulated	NULL
cells	NULL
compared	NULL
with	NULL
unstimulated	NULL
cell	NULL
controls	NULL
.	NULL

Cyclic	NULL
AMP	NULL
assay	NULL
A	NULL
competitive	NULL
solid	NULL
phase	NULL
ELISA	NULL
with	NULL
a	NULL
sensitivity	NULL
in	NULL
the	NULL
range	NULL
of	NULL
4-1052	NULL
pg	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
cAMP	NULL
in	NULL
PBMC	NULL
(	NULL
Biotrak	NULL
EIA	NULL
system	NULL
,	NULL
Amersham	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
1	NULL
x	NULL
10°	NULL
PBMC	NULL
546	NULL
D.	NULL
J.	NULL
Guyot	NULL
et	NULL
al	NULL
.	NULL

were	NULL
stimulated	NULL
for	NULL
periods	NULL
ranging	NULL
from	NULL
5	NULL
min	NULL
to	NULL
4	NULL
hr	NULL
,	NULL
harvested	NULL
,	NULL
washed	NULL
twice	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
resuspended	NULL
in	NULL
cold	NULL
60	NULL
%	NULL
ethanol	NULL
and	NULL
held	NULL
overnight	NULL
at	NULL
-20°	NULL
to	NULL
extract	NULL
cAMP	NULL
.	NULL

Cell	NULL
debris	NULL
was	NULL
pelleted	NULL
and	NULL
the	NULL
supernatant	NULL
lyophilized	NULL
.	NULL

The	NULL
dried	NULL
pellet	NULL
containing	NULL
cAMP	NULL
was	NULL
dissolved	NULL
in	NULL
0:5	NULL
ml	NULL
assay	NULL
buffer	NULL
and	NULL
the	NULL
assay	NULL
performed	NULL
according	NULL
to	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
Whole	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
5x	NULL
10°	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
PBMC	NULL
and	NULL
probed	NULL
for	NULL
CREB	NULL
and	NULL
serine	NULL
133	NULL
P-CREB	NULL
proteins	NULL
according	NULL
to	NULL
manufacturers	NULL
instructions	NULL
{	NULL
PhosphoPlus	NULL
Creb	NULL
Antibody	NULL
kit	NULL
,	NULL
New	NULL
England	NULL
BioLabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
.	NULL
)	NULL

.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
pelleted	NULL
,	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
lysed	NULL
in	NULL
200	NULL
ul	NULL
of	NULL
sodium	NULL
dodecyl	NULL
sulphate	NULL
(	NULL
SDS	NULL
)	NULL
sample	NULL
buffer	NULL
,	NULL
quantified	NULL
by	NULL
spectrophotometry	NULL
and	NULL
10	NULL
ug	NULL
resolved	NULL
in	NULL
a	NULL
denaturing	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
PAGE	NULL
)	NULL
minigel	NULL
(	NULL
Readygel	NULL
,	NULL
Gibco	NULL
BRL	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
.	NULL
)	NULL

.	NULL

Proteins	NULL
were	NULL
transferred	NULL
overnight	NULL
to	NULL
polyvinylidene	NULL
fluoride	NULL
membranes	NULL
(	NULL
Immobilon	NULL
P	NULL
,	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
.	NULL
)	NULL

and	NULL
CREB	NULL
or	NULL
P-CREB	NULL
proteins	NULL
detected	NULL
using	NULL
a	NULL
1:2000	NULL
dilution	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
specific	NULL
for	NULL
either	NULL
CREB	NULL
or	NULL
serine	NULL
133	NULL
P-CREB	NULL
proteins	NULL
followed	NULL
by	NULL
1:2000	NULL
of	NULL
an	NULL
alkaline	NULL
phosphatase-conjugated	NULL
antirabbit	NULL
secondary	NULL
antibody	NULL
.	NULL

The	NULL
antibody	NULL
used	NULL
to	NULL
detect	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
CREB	NULL
also	NULL
reacts	NULL
with	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
the	NULL
closely	NULL
related	NULL
ATF-1	NULL
protein	NULL
.	NULL

Chemiluminescence	NULL
was	NULL
detected	NULL
by	NULL
autoradiography	NULL
and	NULL
bands	NULL
quantified	NULL
by	NULL
densitometric	NULL
scanning	NULL
.	NULL

Consistency	NULL
of	NULL
loading	NULL
was	NULL
verified	NULL
by	NULL
Coomassie	NULL
staining	NULL
of	NULL
gels	NULL
run	NULL
concurrently	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
inhibitors	NULL
of	NULL
protein	NULL
kinases	NULL
(	NULL
Calbiochem	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
were	NULL
added	NULL
16	NULL
hr	NULL
prior	NULL
to	NULL
placing	NULL
cells	NULL
in	NULL
stimulation	NULL
protocols	NULL
.	NULL

Starting	NULL
concentrations	NULL
of	NULL
inhibitors	NULL
were	NULL
obtained	NULL
from	NULL
referenced	NULL
studies	NULL
and	NULL
concentrations	NULL
subsequently	NULL
optimized	NULL
in	NULL
PBMC	NULL
choosing	NULL
the	NULL
concentration	NULL
which	NULL
maximally	NULL
modulated	NULL
P-CREB	NULL
levels	NULL
following	NULL
CD2	NULL
receptor	NULL
signalling	NULL
.	NULL

The	NULL
PTK	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
(	NULL
ICs	NULL
,	NULL
70-900	NULL
nm	NULL
)	NULL
,	NULL
which	NULL
binds	NULL
and	NULL
promotes	NULL
degradation	NULL
of	NULL
PTKs	NULL
was	NULL
used	NULL
at	NULL
2	NULL
um	NULL
``	NULL
The	NULL
PKC	NULL
inhibitor	NULL
,	NULL
calphostin	NULL
C	NULL
,	NULL
which	NULL
causes	NULL
irreversible	NULL
oxidative	NULL
modification	NULL
by	NULL
binding	NULL
the	NULL
regulatory	NULL
domain	NULL
of	NULL
PKC	NULL
was	NULL
used	NULL
at	NULL
0-5	NULL
uM	NULL
(	NULL
ICs	NULL
,	NULL
0-05	NULL
um	NULL
)	NULL
.	NULL

The	NULL
phosphorothiol-ated	NULL
Rp-isomer	NULL
of	NULL
cAMP	NULL
,	NULL
which	NULL
acts	NULL
as	NULL
a	NULL
PKA	NULL
specific	NULL
inhibitor	NULL
by	NULL
binding	NULL
and	NULL
inhibiting	NULL
release	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
was	NULL
used	NULL
at	NULL
150	NULL
um	NULL
(	NULL
ICs	NULL
,	NULL
11	NULL
um	NULL
)	NULL
.	NULL

The	NULL
CaM	NULL
kinase	NULL
pathway	NULL
inhibitor	NULL
,	NULL
CsA	NULL
which	NULL
blocks	NULL
calcineurin-mediated	NULL
activation	NULL
of	NULL
the	NULL
CaM	NULL
kinases	NULL
was	NULL
used	NULL
at	NULL
2	NULL
ug/ml	NULL
.	NULL

These	NULL
concentrations	NULL
of	NULL
inhibitors	NULL
were	NULL
determined	NULL
in	NULL
preliminary	NULL
studies	NULL
to	NULL
affect	NULL
cellular	NULL
proliferation	NULL
(	NULL
determined	NULL
by	NULL
[	NULL
PH	NULL
]	NULL
thymidine	NULL
incorporation	NULL
)	NULL
but	NULL
did	NULL
not	NULL
reduced	NULL
cell	NULL
viability	NULL
(	NULL
as	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
)	NULL
after	NULL
incubation	NULL
with	NULL
the	NULL
treatments	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
1x	NULL
10	NULL
'	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
PBMC	NULL
and	NULL
evaluated	NULL
as	NULL
described	NULL
``	NULL
using	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
lysate	NULL
,	NULL
1	NULL
ug	NULL
dI-dC	NULL
and	NULL
40000	NULL
c.p.m	NULL
.	NULL

of	NULL
*P	NULL
end-labelled	NULL
CRE-specific	NULL
or	NULL
mutant	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
.	NULL
)	NULL

.	NULL

Lysates	NULL
were	NULL
quantified	NULL
by	NULL
Micro	NULL
BCA	NULL
Protein	NULL
Assay	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
and	NULL
compared	NULL
to	NULL
Coomassie	NULL
staining	NULL
of	NULL
denaturing	NULL
protein	NULL
gels	NULL
run	NULL
concurrently	NULL
to	NULL
visually	NULL
assess	NULL
protein	NULL
quality	NULL
and	NULL
quantity	NULL
.	NULL

To	NULL
identify	NULL
CREB-containing	NULL
complexes	NULL
,	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
supershifted	NULL
with	NULL
1	NULL
ul	NULL
of	NULL
anti-CREB	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Where	NULL
indi-cated	NULL
,	NULL
specificity	NULL
of	NULL
binding	NULL
was	NULL
determined	NULL
in	NULL
competition	NULL
experiments	NULL
adding	NULL
50	NULL
ng	NULL
of	NULL
unlabelled	NULL
oligonucleotide	NULL
probe	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
radiolabelled	NULL
probe	NULL
.	NULL

Following	NULL
polyacryl-amide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
specific	NULL
activity	NULL
determined	NULL
by	NULL
phosphor-imaging	NULL
analysis	NULL
(	NULL
Phosphor-imager	NULL
model	NULL
445-PC	NULL
,	NULL
analysed	NULL
by	NULL
ImageQuaNT	NULL
version	NULL
4.1b	NULL
,	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunneyvale	NULL
CA	NULL
.	NULL
)	NULL

.	NULL

RESULTS	NULL
Receptor	NULL
cross-linking	NULL
increases	NULL
[	NULL
PH	NULL
|	NULL
thymidine	NULL
incorporation	NULL
in	NULL
stimulated	NULL
PBMC	NULL
The	NULL
CD2	NULL
receptor	NULL
functions	NULL
both	NULL
as	NULL
an	NULL
adhesion	NULL
molecule	NULL
and	NULL
in	NULL
antigen-specific	NULL
and	NULL
antigen-independent	NULL
lymphocyte	NULL
activation	NULL
.	NULL

While	NULL
the	NULL
signalling	NULL
pathways	NULL
effecting	NULL
these	NULL
functions	NULL
likely	NULL
diverge	NULL
,	NULL
lymphocyte	NULL
proliferation	NULL
is	NULL
a	NULL
measurable	NULL
endpoint	NULL
of	NULL
cell	NULL
activation	NULL
and	NULL
provided	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
receptor	NULL
stimulation	NULL
in	NULL
these	NULL
studies	NULL
.	NULL

As	NULL
a	NULL
measure	NULL
of	NULL
proliferation	NULL
,	NULL
we	NULL
determined	NULL
[	NULL
PH	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
quiescent	NULL
and	NULL
stimulated	NULL
PBMC	NULL
after	NULL
72	NULL
hr	NULL
in	NULL
culture	NULL
with	NULL
anti-CD2	NULL
or	NULL
anti-CD3	NULL
mAbs	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
exogenously	NULL
added	NULL
IL-2	NULL
to	NULL
avoid	NULL
costimulatory	NULL
effects	NULL
of	NULL
the	NULL
IL-2	NULL
pathway	NULL
.	NULL

The	NULL
TIlI.1	NULL
and	NULL
TIl.2	NULL
pair	NULL
of	NULL
anti-CD2	NULL
mAbs	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
increased	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
an	NULL
average	NULL
sixfold	NULL
over	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
prl	NULL
control	NULL
stimulated	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
CD2	NULL
cross-linking	NULL
increased	NULL
[	NULL
PH	NULL
]	NULL
Jthymidine	NULL
incorporation	NULL
3+3-fold	NULL
,	NULL
from	NULL
1488	NULL
+208	NULL
c.p.m	NULL
.	NULL

(	NULL
c.p.m	NULL
.	NULL

+SD	NULL
)	NULL
in	NULL
the	NULL
quiescent	NULL
pri-stimulated	NULL
cell	NULL
control	NULL
to	NULL
4965	NULL
+745	NULL
c.p.m	NULL
.	NULL

in	NULL
the	NULL
CD2-stimulated	NULL
population	NULL
.	NULL

PBMC	NULL
proliferated	NULL
more	NULL
strongly	NULL
in	NULL
response	NULL
to	NULL
anti-CD3	NULL
mAbs	NULL
.	NULL

CD3	NULL
cross-linking	NULL
increased	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
an	NULL
average	NULL
38-fold	NULL
,	NULL
to	NULL
48	NULL
675+5169	NULL
c.p.m	NULL
.	NULL

in	NULL
the	NULL
experiment	NULL
shown	NULL
.	NULL

Mitogenic	NULL
stimulation	NULL
with	NULL
phytohaemagglutinin	NULL
{	NULL
(	NULL
PHA	NULL
)	NULL
increased	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
an	NULL
average	NULL
50-fold	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
cAMP	NULL
on	NULL
cell	NULL
proliferation	NULL
,	NULL
direct	NULL
activation	NULL
of	NULL
adenylate	NULL
cyclase	NULL
with	NULL
forskolin	NULL
decreased	NULL
spontaneous	NULL
[	NULL
*H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
290	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
cAMP	NULL
We	NULL
previously	NULL
demonstrated	NULL
increased	NULL
HTLV-1	NULL
transcription	NULL
within	NULL
24	NULL
hr	NULL
of	NULL
CD2	NULL
but	NULL
not	NULL
CD3	NULL
cross-linking	NULL
of	NULL
immortalized	NULL
HTLV-1-infected	NULL
lymphocyte	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
cotransfected	NULL
with	NULL
the	NULL
HTLV-1	NULL
promoter	NULL
and	NULL
a	NULL
Tax-expressing	NULL
plasmid	NULL
.	NULL

*	NULL
Significant	NULL
levels	NULL
of	NULL
reporter	NULL
gene	NULL
activity	NULL
required	NULL
expression	NULL
of	NULL
viral	NULL
Tax	NULL
responsive	NULL
elements	NULL
.	NULL

These	NULL
elements	NULL
are	NULL
homologous	NULL
to	NULL
cellular	NULL
cAMP	NULL
response	NULL
elements	NULL
and	NULL
bind	NULL
the	NULL
CREB/ATF	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

While	NULL
TRE-mediated	NULL
transcription	NULL
is	NULL
not	NULL
strictly	NULL
dependent	NULL
on	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
,	NULL
cAMP	NULL
augments	NULL
transcription	NULL
from	NULL
TRE	NULL
sites	NULL
.	NULL

Because	NULL
CD2	NULL
,	NULL
but	NULL
not	NULL
CD3	NULL
,	NULL
cross-linking	NULL
increased	NULL
HTLV-1	NULL
transcription	NULL
,	NULL
we	NULL
postulated	NULL
that	NULL
CD2	NULL
,	NULL
but	NULL
not	NULL
CD3	NULL
,	NULL
cross-linking	NULL
induced	NULL
cAMP	NULL
.	NULL

We	NULL
therefore	NULL
evaluated	NULL
levels	NULL
of	NULL
cAMP	NULL
at	NULL
15	NULL
,	NULL
30	NULL
,	NULL
60	NULL
,	NULL
120	NULL
,	NULL
180	NULL
,	NULL
and	NULL
240	NULL
min	NULL
following	NULL
CD2	NULL
and	NULL
CD3	NULL
receptor	NULL
stimulation	NULL
of	NULL
primary	NULL
human	NULL
PBMC	NULL
.	NULL

Consistent	NULL
with	NULL
results	NULL
by	NULL
Hahn	NULL
et	NULL
al	NULL
.	NULL
``	NULL

CD2	NULL
signalling	NULL
induced	NULL
peaked	NULL
increases	NULL
(	NULL
average	NULL
of	NULL
fourfold	NULL
)	NULL
in	NULL
cAMP	NULL
within	NULL
15	NULL
min	NULL
©1998	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
95	NULL
,	NULL
544-	NULL
552	NULL
CD2	NULL
signalling	NULL
induces	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
547	NULL
120	NULL
100	NULL
80	NULL
60	NULL
40	NULL
20	NULL
C.p.m	NULL
.	NULL

[	NULL
HJthymidinex	NULL
1000	NULL
Control	NULL
Anti-CO2	NULL
Anti-CD3	NULL
PHA	NULL
Forskolin	NULL
Figure	NULL
1	NULL
.	NULL

Receptor	NULL
cross-linking	NULL
increases	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
PBMC	NULL
.	NULL

Proliferation	NULL
was	NULL
evaluated	NULL
in	NULL
PBMC	NULL
by	NULL
determining	NULL
c.p.m	NULL
.	NULL

[	NULL
}	NULL
H	NULL
]	NULL
}	NULL
thymidine	NULL
incorporated	NULL
after	NULL
72	NULL
hr	NULL
in	NULL
culture	NULL
with	NULL
control	NULL
,	NULL
anti-CD2	NULL
or	NULL
anti-CD3	NULL
mAbs	NULL
,	NULL
PHA	NULL
or	NULL
forskolin	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
exogeously	NULL
added	NULL
IL-2	NULL
to	NULL
avoid	NULL
costimulatory	NULL
effects	NULL
of	NULL
the	NULL
IL-2	NULL
pathway	NULL
.	NULL

Triplicate	NULL
wells	NULL
were	NULL
stimulated	NULL
as	NULL
indicated	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
pulsed	NULL
with	NULL
1	NULL
uCi/well	NULL
[	NULL
*H	NULL
]	NULL
thymidine	NULL
for	NULL
the	NULL
final	NULL
4	NULL
hr	NULL
in	NULL
culture	NULL
,	NULL
harvested	NULL
onto	NULL
glass	NULL
fibre	NULL
filters	NULL
and	NULL
c.p.m	NULL
.	NULL

determined	NULL
by	NULL
scintillation	NULL
counting	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
presented	NULL
,	NULL
the	NULL
c.p.m	NULL
.	NULL

SD	NULL
of	NULL
triplicate	NULL
pri-stimulated	NULL
controls	NULL
averaged	NULL
1488	NULL
+208	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
,	NULL
pairs	NULL
of	NULL
anti-CD2	NULL
mAbs	NULL
increased	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
3:3-fold	NULL
(	NULL
4965	NULL
c.p.m	NULL
.	NULL

+745	NULL
)	NULL
.	NULL

On	NULL
average	NULL
,	NULL
CD2	NULL
cross-linking	NULL
increased	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
sixfold	NULL
,	NULL
with	NULL
a	NULL
range	NULL
of	NULL
2-10-fold	NULL
in	NULL
three	NULL
experiments	NULL
.	NULL

CD3	NULL
cross-linking	NULL
increased	NULL
[	NULL
*H	NULL
thymidine	NULL
incorporation	NULL
-	NULL
to	NULL
48	NULL
675+5169	NULL
c.p.m	NULL
.	NULL

,	NULL
consistent	NULL
with	NULL
the	NULL
average	NULL
38-fold	NULL
increase	NULL
observed	NULL
in	NULL
three	NULL
experiments	NULL
(	NULL
range	NULL
24-59-fold	NULL
)	NULL
.	NULL

PHA	NULL
increased	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
62-fold	NULL
in	NULL
the	NULL
experiment	NULL
presented	NULL
,	NULL
to	NULL
91963+4735	NULL
c.p.m	NULL
.	NULL

(	NULL
average	NULL
50-fold	NULL
increase	NULL
;	NULL
range	NULL
29-68-fold	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
cAMP	NULL
on	NULL
cell	NULL
proliferation	NULL
(	NULL
54-55	NULL
)	NULL
,	NULL
forskolin	NULL
decreased	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
87	NULL
%	NULL
(	NULL
193	NULL
c.p.m	NULL
.	NULL

+13	NULL
;	NULL
range	NULL
82-90	NULL
%	NULL
decrease	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
from	NULL
one	NULL
of	NULL
three	NULL
representative	NULL
experiments	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
paired	NULL
analysis	NULL
of	NULL
variance	NULL
for	NULL
data	NULL
from	NULL
all	NULL
three	NULL
experiments	NULL
.	NULL

*P	NULL
<	NULL
0-001	NULL
.	NULL

in	NULL
culture	NULL
(	NULL
range	NULL
two-	NULL
to	NULL
sevenfold	NULL
)	NULL
.	NULL

While	NULL
the	NULL
level	NULL
of	NULL
cAMP	NULL
varied	NULL
between	NULL
the	NULL
three	NULL
experiments	NULL
performed	NULL
,	NULL
pri-stimulated	NULL
controls	NULL
averaged	NULL
121+13	NULL
fmol	NULL
cAMP/2	NULL
x	NULL
10°	NULL
cells	NULL
after	NULL
15	NULL
min	NULL
in	NULL
culture	NULL
.	NULL

CD2	NULL
cross-linking	NULL
increased	NULL
cAMP	NULL
to	NULL
an	NULL
average	NULL
483	NULL
+394	NULL
fmol	NULL
cAMP/2	NULL
x	NULL
10°	NULL
cells	NULL
in	NULL
the	NULL
three	NULL
experiments	NULL
performed	NULL
.	NULL

Direct	NULL
activation	NULL
of	NULL
adenylate	NULL
cyclase	NULL
with	NULL
forskolin	NULL
increased	NULL
cAMP	NULL
approximately	NULL
twofold	NULL
(	NULL
range	NULL
nought	NULL
to	NULL
threefold	NULL
;	NULL
average	NULL
269+150	NULL
fmol	NULL
cAMP/2	NULL
x	NULL
10°	NULL
cells	NULL
)	NULL
.	NULL

This	NULL
twofold	NULL
increase	NULL
was	NULL
considered	NULL
physiologically	NULL
significant	NULL
as	NULL
it	NULL
correlated	NULL
with	NULL
a	NULL
90	NULL
%	NULL
reduction	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

No	NULL
increase	NULL
in	NULL
cAMP	NULL
was	NULL
observed	NULL
following	NULL
treatment	NULL
with	NULL
PHA	NULL
or	NULL
anti-CD3	NULL
mAbs	NULL
.	NULL

CD2	NULL
stimulation	NULL
increased	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
The	NULL
cAMP	NULL
signalling	NULL
pathway	NULL
is	NULL
initiated	NULL
with	NULL
ligand	NULL
binding	NULL
to	NULL
specific	NULL
membrane	NULL
receptors	NULL
which	NULL
activate	NULL
adenylate	NULL
cyclase	NULL
and	NULL
generate	NULL
cAMP	NULL
.	NULL

Two	NULL
molecules	NULL
of	NULL
cAMP	NULL
bind	NULL
the	NULL
regulatory	NULL
subunit	NULL
of	NULL
PKA	NULL
,	NULL
releasing	NULL
the	NULL
catalytic	NULL
subunit	NULL
which	NULL
diffuses	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
phosphorylates	NULL
a	NULL
number	NULL
of	NULL
nuclear	NULL
proteins	NULL
,	NULL
including	NULL
CREB	NULL
and	NULL
ATF-l.	NULL
Phosphorylation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
CREB	NULL
at	NULL
serine	NULL
©1998	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
95	NULL
,	NULL
544-552	NULL
(	NULL
a	NULL
)	NULL
Time	NULL
Time	NULL
Ihr	NULL
+	NULL
0	NULL
C	NULL
CD2	NULL
CD3	NULL
PHA	NULL
Fsk	NULL
P-CREB	NULL
_-	NULL
«	NULL
With	NULL
Ce	NULL
HD	NULL
«	NULL
~~	NULL
P-ATF-1	NULL
.	NULL

iii	NULL
insu	NULL
waite	NULL
(	NULL
b	NULL
)	NULL
0	NULL
Time	NULL
thr	NULL
+	NULL
0	NULL
C	NULL
CD2	NULL
CD3	NULL
PHA	NULL
Fsk	NULL
Cres	NULL
@	NULL
pp	NULL
aap	NULL
aap	NULL
aao	NULL
aw	NULL
»	NULL
t	NULL
oh	NULL
ATF	NULL
Figure	NULL
2	NULL
.	NULL

CD2	NULL
cross-linking	NULL
increases	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
and	NULL
ATF-1	NULL
proteins	NULL
detected	NULL
by	NULL
immunoblot	NULL
assay	NULL
.	NULL

(	NULL
a	NULL
)	NULL
PBMC	NULL
were	NULL
stimulated	NULL
with	NULL
control	NULL
,	NULL
anti-CD2	NULL
or	NULL
anti-CD3	NULL
mAbs	NULL
,	NULL
PHA	NULL
or	NULL
forskolin	NULL
as	NULL
indicated	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
harvested	NULL
1	NULL
hr	NULL
after	NULL
stimulation	NULL
and	NULL
probed	NULL
with	NULL
P-CREB/P-ATF-specific	NULL
antibody	NULL
.	NULL

Chemiluminescence	NULL
was	NULL
detected	NULL
by	NULL
autoradiography	NULL
and	NULL
band	NULL
density	NULL
determined	NULL
by	NULL
densitometric	NULL
scanning	NULL
of	NULL
autoradiographs	NULL
.	NULL

Lane	NULL
1	NULL
contains	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
forskolin-treated	NULL
SK-N-MC	NULL
cell	NULL
lysate	NULL
included	NULL
with	NULL
the	NULL
PhosphoPlus	NULL
CREB	NULL
(	NULL
serl33	NULL
)	NULL
Antibody	NULL
kit	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
(	NULL
+	NULL
)	NULL
.	NULL

Lysates	NULL
from	NULL
cells	NULL
harvested	NULL
at	NULL
time	NULL
0	NULL
and	NULL
from	NULL
the	NULL
pri	NULL
mAb	NULL
control	NULL
stimulated	NULL
cells	NULL
(	NULL
c	NULL
)	NULL
after	NULL
1	NULL
hr	NULL
in	NULL
culture	NULL
indicate	NULL
low	NULL
levels	NULL
of	NULL
P-CREB	NULL
and	NULL
P-ATF-1	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
an	NULL
eightfold	NULL
increase	NULL
in	NULL
P-CREB	NULL
and	NULL
P-ATF-1	NULL
were	NULL
observed	NULL
following	NULL
anti-CD2	NULL
or	NULL
PHA	NULL
treatment	NULL
(	NULL
range	NULL
2-19-fold	NULL
)	NULL
.	NULL

No	NULL
change	NULL
in	NULL
P-CREB	NULL
was	NULL
observed	NULL
following	NULL
CD3	NULL
cross-linking	NULL
.	NULL

Forskolin	NULL
treatment	NULL
increased	NULL
P-CREB	NULL
levels	NULL
approximately	NULL
threefold	NULL
(	NULL
range	NULL
nought	NULL
to	NULL
sixfold	NULL
)	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
five	NULL
separate	NULL
experiments	NULL
.	NULL

(	NULL
b	NULL
)	NULL
To	NULL
determine	NULL
if	NULL
the	NULL
increase	NULL
in	NULL
P-CREB	NULL
observed	NULL
was	NULL
due	NULL
to	NULL
increased	NULL
level	NULL
of	NULL
CREB	NULL
protein	NULL
or	NULL
to	NULL
post-translational	NULL
modification	NULL
,	NULL
separate	NULL
immunoblots	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
same	NULL
lysates	NULL
and	NULL
probed	NULL
with	NULL
a	NULL
CREB-specific	NULL
antibody	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
level	NULL
of	NULL
total	NULL
CREB	NULL
protein	NULL
was	NULL
observed	NULL
following	NULL
receptor	NULL
stimulation	NULL
,	NULL
mitogen	NULL
or	NULL
forskolin	NULL
treatment	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
from	NULL
lysates	NULL
pictured	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
(	NULL
a	NULL
)	NULL
,	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
five	NULL
separate	NULL
experiments	NULL
.	NULL

133	NULL
is	NULL
considered	NULL
the	NULL
primary	NULL
mechanism	NULL
regulating	NULL
transcription	NULL
from	NULL
promoters	NULL
containing	NULL
cAMP	NULL
responsive	NULL
elements	NULL
.	NULL
``	NULL

As	NULL
CD2	NULL
receptor	NULL
stimulation	NULL
increased	NULL
cAMP	NULL
fourfold	NULL
within	NULL
15	NULL
min	NULL
in	NULL
culture	NULL
,	NULL
we	NULL
postulated	NULL
CD2	NULL
cross-linking	NULL
would	NULL
be	NULL
temporally	NULL
associated	NULL
with	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

We	NULL
evaluated	NULL
P-CREB	NULL
at	NULL
0-5	NULL
,	NULL
1	NULL
,	NULL
4	NULL
and	NULL
24	NULL
hr	NULL
following	NULL
CD2	NULL
or	NULL
CD3	NULL
cross-linking	NULL
.	NULL

CD2	NULL
stimulation	NULL
increased	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
an	NULL
average	NULL
eightfold	NULL
over	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
control	NULL
pri-stimulated	NULL
cells	NULL
within	NULL
1	NULL
hr	NULL
in	NULL
culture	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
range	NULL
2-19-fold	NULL
)	NULL
.	NULL

P-CREB	NULL
returned	NULL
to	NULL
basal	NULL
levels	NULL
within	NULL
4	NULL
hr	NULL
of	NULL
receptor	NULL
cross-linking	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
change	NULL
in	NULL
level	NULL
of	NULL
CREB	NULL
phosphorylation	NULL
was	NULL
observed	NULL
following	NULL
CD3	NULL
cross-linking	NULL
of	NULL
primary	NULL
human	NULL
PBMC	NULL
.	NULL

Interestingly	NULL
,	NULL
mitogenic	NULL
stimulation	NULL
with	NULL
PHA	NULL
increased	NULL
P-CREB	NULL
with	NULL
stoichiometry	NULL
comparable	NULL
to	NULL
that	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
even	NULL
though	NULL
PHA	NULL
treatment	NULL
was	NULL
not	NULL
associated	NULL
with	NULL
induction	NULL
of	NULL
cAMP	NULL
.	NULL

Forskolin	NULL
treatment	NULL
increased	NULL
P-CREB	NULL
approximately	NULL
threefold	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
lower	NULL
level	NULL
of	NULL
cAMP	NULL
observed	NULL
following	NULL
forskolin	NULL
treatment	NULL
.	NULL

Consistent	NULL
with	NULL
previous	NULL
reports	NULL
of	NULL
post-transcriptional	NULL
regulation	NULL
of	NULL
548	NULL
D.	NULL
J.	NULL
Guyot	NULL
et	NULL
al	NULL
.	NULL

CREB	NULL
,	NULL
``	NULL
no	NULL
change	NULL
in	NULL
total	NULL
level	NULL
of	NULL
CREB	NULL
protein	NULL
was	NULL
demonstrated	NULL
following	NULL
receptor	NULL
cross-linking	NULL
(	NULL
Fig	NULL
.	NULL

2b	NULL
)	NULL
.	NULL

Inhibitors	NULL
of	NULL
protein	NULL
kinases	NULL
differentially	NULL
modulate	NULL
lymphocyte	NULL
The	NULL
eightfold	NULL
increase	NULL
in	NULL
P-CREB	NULL
detected	NULL
following	NULL
CD2	NULL
cross-linking	NULL
was	NULL
temporally	NULL
associated	NULL
with	NULL
a	NULL
fourfold	NULL
increase	NULL
in	NULL
cAMP	NULL
.	NULL

However	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
cAMP	NULL
was	NULL
observed	NULL
following	NULL
PHA	NULL
treatment	NULL
despite	NULL
consistently	NULL
elevated	NULL
levels	NULL
of	NULL
P-CREB	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
in	NULL
lymphocytes	NULL
occurs	NULL
through	NULL
both	NULL
cAMP-dependent	NULL
and	NULL
cAMP-independent	NULL
pathways	NULL
.	NULL

While	NULL
PKA	NULL
is	NULL
postulated	NULL
to	NULL
be	NULL
the	NULL
major	NULL
mechanism	NULL
regulating	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
ser-133	NULL
in	NULL
vivo	NULL
,	NULL
PKC	NULL
,	NULL
CaM	NULL
kinases	NULL
,	NULL
casein	NULL
kinases	NULL
I	NULL
,	NULL
II	NULL
and	NULL
IV	NULL
have	NULL
all	NULL
been	NULL
demonstrated	NULL
to	NULL
phosphorylate	NULL
CREB	NULL
in	NULL
vitro	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
contributions	NULL
of	NULL
these	NULL
protein	NULL
kinase	NULL
signalling	NULL
cascades	NULL
in	NULL
primary	NULL
human	NULL
PBMC	NULL
,	NULL
we	NULL
pretreated	NULL
PBMC	NULL
with	NULL
different	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
for	NULL
16	NULL
hr	NULL
before	NULL
placing	NULL
them	NULL
in	NULL
CD2	NULL
receptor	NULL
cross-linking	NULL
protocols	NULL
.	NULL

To	NULL
control	NULL
for	NULL
inhibition	NULL
of	NULL
protein	NULL
kinase	NULL
signalling	NULL
we	NULL
evaluated	NULL
*H-thymidine	NULL
incorporation	NULL
in	NULL
treated	NULL
and	NULL
untreated	NULL
PBMC	NULL
after	NULL
72	NULL
hr	NULL
in	NULL
culture	NULL
with	NULL
control	NULL
or	NULL
anti-CD2	NULL
mAbs	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
[	NULL
°H	NULL
thymidine	NULL
incorporation	NULL
in	NULL
untreated	NULL
control	NULL
cells	NULL
averaged	NULL
1488	NULL
+208	NULL
c.p.m..	NULL
CD2	NULL
receptor	NULL
cross-linking	NULL
increased	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
approximately	NULL
threefold	NULL
,	NULL
to	NULL
4965	NULL
+745	NULL
c.p.m..	NULL
Pretreatment	NULL
of	NULL
PBMC	NULL
with	NULL
2	NULL
um	NULL
of	NULL
the	NULL
PTK	NULL
inhibitor	NULL
,	NULL
herbimycin	NULL
A	NULL
decreased	NULL
the	NULL
level	NULL
of	NULL
]	NULL
thymidine	NULL
incorporation	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
an	NULL
average	NULL
92	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
;	NULL
range	NULL
88-94	NULL
%	NULL
reduction	NULL
)	NULL
to	NULL
351	NULL
+76	NULL
c.p.m..	NULL
Inhibition	NULL
of	NULL
PKC	NULL
signalling	NULL
with	NULL
0:5	NULL
mm	NULL
calphostin	NULL
C	NULL
decreased	NULL
the	NULL
[	NULL
PH	NULL
]	NULL
thymidine	NULL
incorporation	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
an	NULL
average	NULL
89	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
;	NULL
515	NULL
+93	NULL
c.p.m	NULL
.	NULL

;	NULL
range	NULL
86-91	NULL
%	NULL
reduction	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
inhibitory	NULL
role	NULL
of	NULL
cAMP	NULL
in	NULL
lymphocytes	NULL
,	NULL
inhibition	NULL
of	NULL
the	NULL
cAMP/PKA	NULL
signalling	NULL
pathway	NULL
with	NULL
_-	NULL
Rp-cAMP	NULL
__	NULL
actually	NULL
_	NULL
increased	NULL
-	NULL
CD2-mediated	NULL
[	NULL
PH	NULL
}	NULL
thymidine	NULL
incorporation	NULL
approximately	NULL
twofold	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
;	NULL
10239	NULL
+1665	NULL
c.p.m	NULL
.	NULL

;	NULL
range	NULL
1+7-2:4-fold	NULL
increase	NULL
)	NULL
.	NULL

In	NULL
separate	NULL
experiments	NULL
,	NULL
2	NULL
ug/ml	NULL
of	NULL
the	NULL
CaM	NULL
kinase	NULL
pathway	NULL
inhibitor	NULL
CsA	NULL
decreased	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
following	NULL
CD2	NULL
cross-linking	NULL
an	NULL
average	NULL
95	NULL
%	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
;	NULL
range	NULL
50-99	NULL
%	NULL
inhibition	NULL
)	NULL
.	NULL

Herbimycin	NULL
A	NULL
inhibits	NULL
CD2	NULL
receptor-mediated	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
The	NULL
src	NULL
family	NULL
PTKs	NULL
p56	NULL
``	NULL
and	NULL
p59	NULL
%	NULL
``	NULL
transmit	NULL
proximal	NULL
membrane	NULL
signals	NULL
through	NULL
the	NULL
CD2	NULL
and	NULL
CD3	NULL
receptors	NULL
,	NULL
suggesting	NULL
that	NULL
PTKs	NULL
transduce	NULL
early	NULL
signals	NULL
culminating	NULL
in	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL
``	NULL

We	NULL
therefore	NULL
evaluated	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
on	NULL
CD2-induced	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
90	NULL
%	NULL
reduction	NULL
in	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
,	NULL
a	NULL
16-hr	NULL
preincubation	NULL
of	NULL
PBMC	NULL
with	NULL
2	NULL
um	NULL
herbimycin	NULL
A	NULL
decreased	NULL
the	NULL
level	NULL
of	NULL
P-CREB	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
an	NULL
average	NULL
80	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

4a	NULL
;	NULL
range	NULL
52-100	NULL
%	NULL
reduction	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
requires	NULL
antecedent	NULL
tyrosine	NULL
kinase	NULL
activation	NULL
.	NULL

14	NULL
7	NULL
12	NULL
]	NULL
o	NULL
1	NULL
S	NULL
p	NULL
€	NULL
103	NULL
%	NULL
1	NULL
©	NULL
1	NULL
£	NULL
4	NULL
6	NULL
-	NULL
81	NULL
€	NULL
k	NULL
2	NULL
1	NULL
€	NULL
5	NULL
£00	NULL
43	NULL
a	NULL
1	NULL
o	NULL
3	NULL
2	NULL
4	NULL
o	NULL
3	NULL
Control	NULL
Anti-CD2	NULL
Rp-cAMP	NULL
Herbimycin	NULL
A	NULL
Calphostin	NULL
C	NULL
Figure	NULL
3	NULL
.	NULL

Effects	NULL
of	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
in	NULL
CD2-mediated	NULL
stimulation	NULL
of	NULL
PBMC	NULL
.	NULL

To	NULL
evaluate	NULL
effectiveness	NULL
of	NULL
protein	NULL
kinase	NULL
inhibition	NULL
,	NULL
[	NULL
PH	NULL
]	NULL
thymidine	NULL
incorporation	NULL
was	NULL
determined	NULL
in	NULL
inhibitor	NULL
treated	NULL
and	NULL
untreated	NULL
PBMC	NULL
following	NULL
CD2	NULL
receptor	NULL
cross-linking	NULL
.	NULL

PBMC	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
inhibitor	NULL
for	NULL
16	NULL
hr	NULL
before	NULL
receptor	NULL
cross-linking	NULL
and	NULL
aliquoted	NULL
in	NULL
triplicate	NULL
into	NULL
stimulation	NULL
protocols	NULL
as	NULL
indicated	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
for	NULL
72	NULL
hr	NULL
with	NULL
control	NULL
or	NULL
anti-CD2	NULL
mAbs	NULL
,	NULL
pulsed	NULL
with	NULL
1	NULL
uCi/well	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
for	NULL
the	NULL
final	NULL
4	NULL
hr	NULL
in	NULL
culture	NULL
,	NULL
harvested	NULL
and	NULL
c.p.m	NULL
.	NULL

[	NULL
H	NULL
}	NULL
thymidine	NULL
determined	NULL
by	NULL
scintillation	NULL
counting	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
from	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
CD2	NULL
receptor	NULL
increased	NULL
[	NULL
*H	NULL
}	NULL
thymidine	NULL
incorporation	NULL
approximately	NULL
three-fold	NULL
.	NULL

Consistent	NULL
with	NULL
inhibition	NULL
of	NULL
CD2	NULL
signal	NULL
transduction	NULL
through	NULL
p56	NULL
``	NULL
or	NULL
p59	NULL
``	NULL
,	NULL
herbimycin	NULL
A	NULL
reduced	NULL
the	NULL
c.p.m	NULL
.	NULL

+	NULL
SD	NULL
[	NULL
PH	NULL
]	NULL
thymidine	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
by	NULL
92	NULL
%	NULL
(	NULL
351	NULL
+76	NULL
c.p.m	NULL
.	NULL

;	NULL
range	NULL
88-94	NULL
%	NULL
reduction	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
PKC	NULL
signalling	NULL
with	NULL
0-5	NULL
mm	NULL
calphostin	NULL
C	NULL
decreased	NULL
CD2-induced	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
an	NULL
average	NULL
89	NULL
%	NULL
(	NULL
515+93	NULL
c.p.m	NULL
.	NULL

,	NULL
range	NULL
86-91	NULL
%	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
inhibitory	NULL
role	NULL
of	NULL
cAMP	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
,	NULL
inhibition	NULL
of	NULL
the	NULL
cAMP/	NULL
PKA	NULL
signalling	NULL
pathway	NULL
with	NULL
Rp-cAMP	NULL
increased	NULL
[	NULL
PH	NULL
]	NULL
thymidine	NULL
incorporation	NULL
twofold	NULL
(	NULL
10239+1665	NULL
c.p.m	NULL
.	NULL

;	NULL
range	NULL
1:7	NULL
2:4-fold	NULL
increase	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
from	NULL
one	NULL
of	NULL
three	NULL
representative	NULL
experiments	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
average	NULL
c.p.m	NULL
.	NULL

[	NULL
*H	NULL
]	NULL
thymidine+SD	NULL
from	NULL
triplicate	NULL
samples	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
paired	NULL
analysis	NULL
of	NULL
variance	NULL
for	NULL
data	NULL
from	NULL
all	NULL
three	NULL
experiments	NULL
performed	NULL
,	NULL
comparing	NULL
c.p.m	NULL
.	NULL
]	NULL

thymidine	NULL
in	NULL
anti-CD2	NULL
stimulated	NULL
cells	NULL
to	NULL
c.p.m	NULL
.	NULL

[	NULL
H	NULL
]	NULL
thymidine	NULL
in	NULL
CD2	NULL
stimulated	NULL
cells	NULL
pretreated	NULL
with	NULL
protein	NULL
kinase	NULL
inhibitor	NULL
.	NULL

*P	NULL
<	NULL
0-01	NULL
.	NULL

At	NULL
the	NULL
concentrations	NULL
used	NULL
the	NULL
inhibitors	NULL
did	NULL
not	NULL
reduce	NULL
cell	NULL
viability	NULL
or	NULL
constitutive	NULL
levels	NULL
of	NULL
CREB	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Rp-cAMP	NULL
partially	NULL
inhibits	NULL
CD2-mediated	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
Phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
is	NULL
postulated	NULL
to	NULL
occur	NULL
in	NULL
vivo	NULL
through	NULL
activation	NULL
of	NULL
the	NULL
cAMP	NULL
dependent	NULL
protein	NULL
kinase	NULL
,	NULL
PKA	NULL
.	NULL

Since	NULL
the	NULL
increase	NULL
in	NULL
P-CREB	NULL
we	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
was	NULL
temporally	NULL
associated	NULL
with	NULL
increased	NULL
cAMP	NULL
,	NULL
we	NULL
evaluated	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
PKA-specific	NULL
inhibitor	NULL
Rp-cAMP	NULL
,	NULL
on	NULL
CD2-induced	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

While	NULL
a	NULL
16-hr	NULL
preincubation	NULL
of	NULL
PBMC	NULL
with	NULL
150	NULL
um	NULL
Rp-cAMP	NULL
increased	NULL
[	NULL
*H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
approximately	NULL
twofold	NULL
,	NULL
Rp-cAMP	NULL
inhibited	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
an	NULL
average	NULL
33	NULL
%	NULL
following	NULL
CD2	NULL
cross-linking	NULL
(	NULL
Fig	NULL
.	NULL

4a	NULL
;	NULL
range	NULL
29-40	NULL
%	NULL
reduction	NULL
)	NULL
.	NULL

Increasing	NULL
concentrations	NULL
of	NULL
©1998	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
95	NULL
,	NULL
544-552	NULL
CD2	NULL
signalling	NULL
induces	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
549	NULL
Rp-cAMP	NULL
did	NULL
not	NULL
further	NULL
suppress	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Inhibitors	NULL
of	NULL
PKC	NULL
and	NULL
CaM	NULL
kinases	NULL
have	NULL
no	NULL
effect	NULL
on	NULL
CD2-mediated	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
Our	NULL
results	NULL
suggest	NULL
either	NULL
that	NULL
inhibition	NULL
of	NULL
the	NULL
PKA	NULL
pathway	NULL
was	NULL
incomplete	NULL
or	NULL
that	NULL
PKA	NULL
is	NULL
not	NULL
the	NULL
sole	NULL
serine/threonine	NULL
kinase	NULL
phosphorylating	NULL
CREB	NULL
in	NULL
vivo	NULL
.	NULL

Cyclic	NULL
AMP-indepen-dent	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
has	NULL
been	NULL
demonstrated	NULL
following	NULL
either	NULL
anti-CD3	NULL
or	NULL
IL-2	NULL
stimulation	NULL
of	NULL
cloned	NULL
T	NULL
lymphocytes	NULL
,	NULL
suggesting	NULL
that	NULL
other	NULL
kinases	NULL
may	NULL
phosphorylate	NULL
CREB	NULL
in	NULL
vivo	NULL
.	NULL
``	NULL

''	NULL
In	NULL
addition	NULL
,	NULL
activation	NULL
of	NULL
PKC	NULL
may	NULL
precede	NULL
activation	NULL
of	NULL
adenylate	NULL
cyclase	NULL
in	NULL
lymphocytes	NULL
following	NULL
CD3	NULL
cross-linking	NULL
.	NULL
``	NULL

Protein	NULL
kinase	NULL
C	NULL
,	NULL
CaM	NULL
kinases	NULL
,	NULL
casein	NULL
kinases	NULL
I	NULL
,	NULL
II	NULL
and	NULL
IV	NULL
have	NULL
all	NULL
been	NULL
demonstrated	NULL
to	NULL
directly	NULL
or	NULL
indirectly	NULL
phosphorylate	NULL
CREB	NULL
in	NULL
vitro	NULL
,	NULL
but	NULL
their	NULL
contribution	NULL
in	NULL
vivo	NULL
has	NULL
not	NULL
been	NULL
determined	NULL
.	NULL

We	NULL
inhibited	NULL
the	NULL
PKC	NULL
and	NULL
CaM	NULL
kinase	NULL
signalling	NULL
pathways	NULL
and	NULL
evaluated	NULL
the	NULL
effects	NULL
on	NULL
CD2-induced	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

While	NULL
pretreatment	NULL
of	NULL
PBMC	NULL
with	NULL
0:5	NULL
mm	NULL
calphostin	NULL
C	NULL
decreased	NULL
CD2-induced	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
80	NULL
%	NULL
,	NULL
calphostin	NULL
C	NULL
increased	NULL
P-CREB	NULL
xzl4-fold	NULL
(	NULL
Fig	NULL
.	NULL

4a	NULL
;	NULL
range	NULL
21-53	NULL
%	NULL
-	NULL
increase	NULL
)	NULL
.	NULL

Figure	NULL
4	NULL
.	NULL

Inhibitors	NULL
of	NULL
cellular	NULL
protein	NULL
kinases	NULL
differentially	NULL
modulate	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

PBMC	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
protein	NULL
kinase	NULL
inhibitor	NULL
for	NULL
16	NULL
hr	NULL
before	NULL
CD2	NULL
receptor	NULL
cross-linking	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
and	NULL
immunoblot	NULL
analysis	NULL
performed	NULL
as	NULL
indicated	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
from	NULL
one	NULL
of	NULL
three	NULL
representative	NULL
experiments	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Both	NULL
herbimycin	NULL
A	NULL
and	NULL
Rp-cAMP	NULL
decrease	NULL
the	NULL
level	NULL
of	NULL
P-CREB	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
.	NULL

Lane	NULL
1	NULL
(	NULL
C	NULL
)	NULL
contains	NULL
lysate	NULL
from	NULL
pri	NULL
control	NULL
stimulated	NULL
cells	NULL
and	NULL
demonstrates	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
P-CREB	NULL
constitutively	NULL
produced	NULL
after	NULL
1	NULL
hr	NULL
in	NULL
culture	NULL
.	NULL

Lanes	NULL
2-5	NULL
were	NULL
treated	NULL
with	NULL
anti-CD2	NULL
mAbs	NULL
either	NULL
with	NULL
or	NULL
without	NULL
pretreatment	NULL
with	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
protein	NULL
kinase	NULL
inhibitor	NULL
.	NULL

Lane	NULL
2	NULL
(	NULL
anti-CD2	NULL
)	NULL
contains	NULL
lysate	NULL
from	NULL
CD2	NULL
stimulated	NULL
cells	NULL
without	NULL
pretreatment	NULL
with	NULL
a	NULL
protein	NULL
kinase	NULL
inhibitor	NULL
,	NULL
and	NULL
demonstrates	NULL
an	NULL
approximately	NULL
sixfold	NULL
increase	NULL
in	NULL
P-CREB	NULL
over	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
unstimulated	NULL
control	NULL
.	NULL

The	NULL
PTK	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
(	NULL
2	NULL
um	NULL
)	NULL
inhibited	NULL
the	NULL
CD2-mediated	NULL
increase	NULL
in	NULL
P-CREB	NULL
an	NULL
average	NULL
80	NULL
%	NULL
(	NULL
range	NULL
52-100	NULL
%	NULL
inhibition	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
PKC	NULL
inhibitor	NULL
calphostin	NULL
C	NULL
(	NULL
0-5	NULL
mm	NULL
)	NULL
consistently	NULL
increased	NULL
the	NULL
level	NULL
of	NULL
P-CREB	NULL
observed	NULL
by	NULL
240	NULL
%	NULL
(	NULL
range	NULL
21-53	NULL
%	NULL
)	NULL
.	NULL

The	NULL
Rp-isomer	NULL
of	NULL
cAMP	NULL
(	NULL
150	NULL
um	NULL
)	NULL
which	NULL
inhibits	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
,	NULL
decreased	NULL
the	NULL
level	NULL
of	NULL
P-CREB	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
an	NULL
average	NULL
33	NULL
%	NULL
(	NULL
range	NULL
29-40	NULL
%	NULL
reduction	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Cyclosporin	NULL
A	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
calcineurin-induced	NULL
CaM	NULL
kinase	NULL
activation	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
CD2-mediated	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

In	NULL
separate	NULL
experiments	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
2	NULL
ug/ml	NULL
CsA	NULL
for	NULL
16	NULL
hr	NULL
before	NULL
placement	NULL
in	NULL
receptor	NULL
stimulation	NULL
protocols	NULL
.	NULL

The	NULL
first	NULL
lane	NULL
contains	NULL
lysate	NULL
from	NULL
pri	NULL
control	NULL
stimulated	NULL
cells	NULL
and	NULL
demonstrates	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
P-CREB	NULL
constitutively	NULL
produced	NULL
after	NULL
1	NULL
hr	NULL
in	NULL
culture	NULL
.	NULL

The	NULL
second	NULL
lane	NULL
contains	NULL
lysate	NULL
from	NULL
CD2-stimulated	NULL
cells	NULL
not	NULL
pretreated	NULL
with	NULL
CsA	NULL
,	NULL
and	NULL
demonstrates	NULL
an	NULL
~10-fold	NULL
increase	NULL
in	NULL
P-CREB	NULL
over	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
pri-stimulated	NULL
control	NULL
.	NULL

Cells	NULL
in	NULL
lane	NULL
3	NULL
were	NULL
treated	NULL
for	NULL
16	NULL
hr	NULL
with	NULL
2	NULL
ug/ml	NULL
CsA	NULL
before	NULL
CD2	NULL
stimulation	NULL
.	NULL

While	NULL
pretreatment	NULL
with	NULL
CsA	NULL
reduced	NULL
[	NULL
'	NULL
H	NULL
incorporation	NULL
by	NULL
90	NULL
%	NULL
,	NULL
CsA	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
level	NULL
of	NULL
P-CREB	NULL
induced	NULL
following	NULL
CD2	NULL
cross-linking	NULL
.	NULL

(	NULL
c	NULL
)	NULL
The	NULL
percentage	NULL
change	NULL
in	NULL
P-CREB	NULL
levels	NULL
as	NULL
determined	NULL
by	NULL
densitometric	NULL
scanning	NULL
of	NULL
autoradiographs	NULL
following	NULL
inhibition	NULL
of	NULL
CD2	NULL
signalling	NULL
is	NULL
averaged	NULL
from	NULL
three	NULL
separate	NULL
trials	NULL
.	NULL

At	NULL
the	NULL
concentrations	NULL
used	NULL
the	NULL
inhibitors	NULL
did	NULL
not	NULL
reduce	NULL
cell	NULL
viability	NULL
or	NULL
constitutive	NULL
levels	NULL
of	NULL
CREB	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

©1998	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
95	NULL
,	NULL
544-552	NULL
Pretreatment	NULL
of	NULL
PBMC	NULL
with	NULL
2	NULL
ug/ml	NULL
of	NULL
the	NULL
CaM	NULL
kinase	NULL
pathway	NULL
inhibitor	NULL
CsA	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
(	NULL
Fig	NULL
.	NULL

4b	NULL
)	NULL
.	NULL

Receptor	NULL
cross-linking	NULL
increased	NULL
CREB	NULL
binding	NULL
to	NULL
a	NULL
CRE	NULL
oligonucleotide	NULL
probe	NULL
While	NULL
CREB	NULL
constitutively	NULL
binds	NULL
DNA	NULL
,	NULL
reports	NULL
conflict	NULL
regarding	NULL
the	NULL
effects	NULL
of	NULL
phosphorylation	NULL
on	NULL
DNA	NULL
binding	NULL
(	NULL
reviewed	NULL
by	NULL
Montminy	NULL
``	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
evaluated	NULL
nuclear	NULL
lysates	NULL
from	NULL
control	NULL
,	NULL
anti-CD2	NULL
and	NULL
anti-CD3	NULL
stimulated	NULL
cells	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
for	NULL
binding	NULL
of	NULL
CREB	NULL
to	NULL
a	NULL
*°P-radiolabelled	NULL
CRE	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

An	NULL
average	NULL
two-	NULL
to	NULL
threefold	NULL
increase	NULL
in	NULL
binding	NULL
was	NULL
observed	NULL
1	NULL
hr	NULL
after	NULL
either	NULL
CD2	NULL
or	NULL
CD3	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
dominant	NULL
CRE	NULL
specific	NULL
band	NULL
(	NULL
pl	NULL
)	NULL
was	NULL
supershifted	NULL
with	NULL
anti-CREB	NULL
mAbs	NULL
,	NULL
demonstrating	NULL
that	NULL
CREB	NULL
is	NULL
a	NULL
major	NULL
constituent	NULL
of	NULL
this	NULL
band	NULL
.	NULL

Specificity	NULL
was	NULL
determined	NULL
by	NULL
eliminating	NULL
DNA	NULL
binding	NULL
with	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
CRE	NULL
probe	NULL
and	NULL
by	NULL
demonstrating	NULL
lack	NULL
of	NULL
binding	NULL
to	NULL
a	NULL
radiolabelled	NULL
mutant	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
while	NULL
lymphocyte	NULL
activation	NULL
increases	NULL
binding	NULL
of	NULL
CREB	NULL
to	NULL
DNA	NULL
,	NULL
this	NULL
occurs	NULL
independently	NULL
of	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

(	NULL
a	NULL
)	NULL
+	NULL
2	NULL
jim	NULL
herbimycin	NULL
+	NULL
0-5mm	NULL
calphostin	NULL
+	NULL
150	NULL
um	NULL
Rp-cAMP	NULL
Anti-CD2	NULL
-	NULL
+	NULL
$	NULL
P-CREB	NULL
P-ATF	NULL
+	NULL
2ug/ml	NULL
CsA	NULL
Anti-CD2	NULL
-	NULL
+	NULL
P-CREB	NULL
P-ATF1	NULL
(	NULL
c	NULL
)	NULL
100	NULL
7	NULL
50	NULL
Change	NULL
(	NULL
%	NULL
)	NULL
-50	NULL
-100	NULL
Herbimycin	NULL
-	NULL
Calphostin	NULL
_	NULL
Rp-cAMP	NULL
CsA	NULL
C	NULL
A	NULL
550	NULL
D.	NULL
J.	NULL
Guyot	NULL
et	NULL
al	NULL
.	NULL

[	NULL
sal	NULL
u	NULL
CC	NULL
o	NULL
8	NULL
O	NULL
CC	NULL
z	NULL
38	NULL
8	NULL
=	NULL
4	NULL
&	NULL
#	NULL
R	NULL
8	NULL
o	NULL
o	NULL
S	NULL
o	NULL
o	NULL
§	NULL
§	NULL
50	NULL
E	NULL
E	NULL
b	NULL
E	NULL
E	NULL
fe	NULL
53	NULL
O	NULL
<	NULL
<	NULL
O	NULL
<	NULL
<	NULL
I	NULL
ha	NULL
3	NULL
Anti-CREB	NULL
|	NULL
-	NULL
0	NULL
-	NULL
0-0	NULL
+o	NULL
+o	NULL
Ay	NULL
m	NULL
cn	NULL
us	NULL
geo	NULL
wan	NULL
.	NULL

**	NULL
p1	NULL
p2	NULL
p4	NULL
3	NULL
p5	NULL
sisted	NULL
150	NULL
125	NULL
~	NULL
100	NULL
£	NULL
$	NULL
-	NULL
75	NULL
C	NULL
©	NULL
€	NULL
o	NULL
-	NULL
50	NULL
25	NULL
o	NULL
Anti-CD2	NULL
Anti-CD3	NULL
Figure	NULL
5	NULL
.	NULL

CD2	NULL
and	NULL
CD3	NULL
cross-linking	NULL
increase	NULL
binding	NULL
of	NULL
CREB	NULL
to	NULL
a	NULL
CRE	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
indicated	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
evaluated	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
for	NULL
binding	NULL
to	NULL
a	NULL
CRE-specific	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

Low	NULL
levels	NULL
of	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
CRE	NULL
probe	NULL
were	NULL
present	NULL
in	NULL
control	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

An	NULL
average	NULL
two-	NULL
to	NULL
threefold	NULL
increase	NULL
in	NULL
binding	NULL
of	NULL
the	NULL
most	NULL
prominent	NULL
specific	NULL
band	NULL
(	NULL
p1	NULL
)	NULL
was	NULL
observed	NULL
following	NULL
either	NULL
CD2	NULL
(	NULL
2-5-fold	NULL
increase	NULL
shown	NULL
)	NULL
or	NULL
CD3	NULL
(	NULL
1+5-fold	NULL
increase	NULL
shown	NULL
)	NULL
cross-linking	NULL
.	NULL

This	NULL
band	NULL
was	NULL
supershifted	NULL
with	NULL
anti-CREB	NULL
antibodies	NULL
,	NULL
demonstrating	NULL
that	NULL
CREB	NULL
is	NULL
a	NULL
component	NULL
of	NULL
band	NULL
pl	NULL
(	NULL
lanes	NULL
4-6	NULL
)	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
eliminated	NULL
with	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
probe	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

No	NULL
binding	NULL
at	NULL
pl	NULL
was	NULL
observed	NULL
to	NULL
a	NULL
radiolabelled	NULL
mutant	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Graph	NULL
represents	NULL
percentage	NULL
change	NULL
in	NULL
pl	NULL
signal	NULL
following	NULL
CD2	NULL
and	NULL
CD3	NULL
stimulation	NULL
measured	NULL
by	NULL
phosphoimage	NULL
analysis	NULL
.	NULL

Results	NULL
from	NULL
this	NULL
experiment	NULL
are	NULL
representative	NULL
of	NULL
those	NULL
obtained	NULL
from	NULL
at	NULL
least	NULL
four	NULL
separate	NULL
experiments	NULL
using	NULL
three	NULL
different	NULL
preparations	NULL
of	NULL
nuclear	NULL
extracts	NULL
.	NULL

DISCUSSION	NULL
Our	NULL
studies	NULL
are	NULL
the	NULL
first	NULL
to	NULL
demonstrate	NULL
a	NULL
temporally	NULL
associated	NULL
eightfold	NULL
increase	NULL
in	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
peaking	NULL
1	NULL
hr	NULL
after	NULL
CD2	NULL
stimulation	NULL
of	NULL
human	NULL
PBMC	NULL
.	NULL

While	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
is	NULL
a	NULL
necessary	NULL
prerequisite	NULL
for	NULL
transcriptional	NULL
activation	NULL
through	NULL
CRE	NULL
promoters	NULL
'	NULL
``	NULL
its	NULL
role	NULL
in	NULL
transcription	NULL
from	NULL
TRE	NULL
sites	NULL
in	NULL
vivo	NULL
is	NULL
less	NULL
clear	NULL
.	NULL

Phosphorylation	NULL
of	NULL
CREB	NULL
is	NULL
not	NULL
an	NULL
absolute	NULL
prerequisite	NULL
for	NULL
transcription	NULL
from	NULL
TRE	NULL
sites	NULL
in	NULL
vitro	NULL
.	NULL
``	NULL

However	NULL
,	NULL
cAMP	NULL
augments	NULL
Tax-dependent	NULL
transcription	NULL
in	NULL
vivo	NULL
,	NULL
suggesting	NULL
that	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
may	NULL
enhance	NULL
dimerization	NULL
of	NULL
transcription	NULL
factors	NULL
and	NULL
recruitment	NULL
of	NULL
the	NULL
transcriptional	NULL
complex	NULL
to	NULL
TRE	NULL
sites	NULL
.	NULL
``	NULL

We	NULL
have	NULL
recently	NULL
reported	NULL
increased	NULL
viral	NULL
transcription	NULL
following	NULL
CD2	NULL
but	NULL
not	NULL
CD3	NULL
stimulation	NULL
of	NULL
immortalized	NULL
lymphocyte	NULL
cell	NULL
lines	NULL
infected	NULL
with	NULL
HTLV-1	NULL
and	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
transiently	NULL
cotransfected	NULL
with	NULL
the	NULL
HTLV-1	NULL
promoter	NULL
and	NULL
transactivating	NULL
protein	NULL
Tax	NULL
.	NULL
``	NULL

Collectively	NULL
,	NULL
these	NULL
studies	NULL
suggest	NULL
a	NULL
P-CREB-dependent	NULL
mechanism	NULL
for	NULL
the	NULL
increase	NULL
in	NULL
HTLV-1	NULL
gene	NULL
transcription	NULL
we	NULL
observed	NULL
following	NULL
CD2	NULL
cross-linking	NULL
of	NULL
HTLV-1	NULL
infected	NULL
lymphocytes	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
the	NULL
use	NULL
of	NULL
primary	NULL
cells	NULL
is	NULL
uncommon	NULL
in	NULL
viral	NULL
transcription	NULL
studies	NULL
.	NULL

Our	NULL
approach	NULL
of	NULL
using	NULL
primary	NULL
cells	NULL
has	NULL
allowed	NULL
us	NULL
to	NULL
identify	NULL
fundamental	NULL
events	NULL
in	NULL
HTLV-1	NULL
transcription	NULL
.	NULL
``	NULL

The	NULL
biological	NULL
relevance	NULL
of	NULL
transcriptional	NULL
regulation	NULL
in	NULL
cell	NULL
lines	NULL
has	NULL
recently	NULL
been	NULL
challenged	NULL
as	NULL
differences	NULL
between	NULL
Jurkat	NULL
and	NULL
PBMC	NULL
signalling	NULL
pathways	NULL
have	NULL
been	NULL
reported	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
use	NULL
primary	NULL
human	NULL
PBMC	NULL
to	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
CD2	NULL
signalling	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
CREB	NULL
.	NULL

Phosphorylation	NULL
of	NULL
CREB	NULL
occurred	NULL
through	NULL
an	NULL
herbimycin	NULL
A	NULL
and	NULL
Rp-cAMP	NULL
sensitive	NULL
pathway	NULL
,	NULL
suggesting	NULL
that	NULL
phosphorylation	NULL
required	NULL
antecedent	NULL
activation	NULL
of	NULL
both	NULL
PTK	NULL
and	NULL
PKA	NULL
.	NULL

Herbimycin	NULL
A	NULL
may	NULL
have	NULL
inhibited	NULL
CD2	NULL
signal	NULL
transduction	NULL
through	NULL
src	NULL
family	NULL
PTK	NULL
at	NULL
the	NULL
cell	NULL
membrane	NULL
or	NULL
inhibited	NULL
cytoplasmic	NULL
PTK	NULL
including	NULL
members	NULL
of	NULL
the	NULL
Tec	NULL
family	NULL
.	NULL
``	NULL

''	NULL
Previous	NULL
studies	NULL
demonstrated	NULL
dependence	NULL
of	NULL
the	NULL
cAMP	NULL
signalling	NULL
pathway	NULL
on	NULL
the	NULL
protein	NULL
phosphatase	NULL
CD45	NULL
,	NULL
implicate	NULL
the	NULL
membrane	NULL
associated	NULL
PTK	NULL
in	NULL
this	NULL
pathway	NULL
.	NULL
``	NULL

Further	NULL
study	NULL
will	NULL
be	NULL
required	NULL
to	NULL
determine	NULL
if	NULL
CD2-directed	NULL
phosphorylation	NULL
occurred	NULL
through	NULL
a	NULL
p56	NULL
``	NULL
**-	NULL
or	NULL
pS59	NULL
``	NULL
-dependent	NULL
pathway	NULL
.	NULL

Phosphorylation	NULL
of	NULL
CREB	NULL
in	NULL
vivo	NULL
is	NULL
postulated	NULL
to	NULL
occur	NULL
through	NULL
PKA-dependent	NULL
pathways	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
hypothesis	NULL
,	NULL
the	NULL
PKA	NULL
specific	NULL
inhibitor	NULL
Rp-cAMP	NULL
reduced	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
an	NULL
average	NULL
33	NULL
%	NULL
.	NULL

However	NULL
,	NULL
increasing	NULL
concentrations	NULL
of	NULL
Rp-cAMP	NULL
did	NULL
not	NULL
further	NULL
decrease	NULL
phosphorylation	NULL
,	NULL
suggesting	NULL
either	NULL
that	NULL
PKA	NULL
was	NULL
incompletely	NULL
inhibited	NULL
by	NULL
Rp-cAMP	NULL
or	NULL
that	NULL
CREB	NULL
is	NULL
also	NULL
phosphorylated	NULL
in	NULL
vivo	NULL
by	NULL
other	NULL
serine/threonine	NULL
kinases	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
hypothesis	NULL
,	NULL
other	NULL
studies	NULL
have	NULL
demonstrated	NULL
cAMP	NULL
-independent	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
following	NULL
anti-CD3	NULL
or	NULL
IL-2	NULL
stimulation	NULL
of	NULL
cloned	NULL
T	NULL
lymphocytes	NULL
suggesting	NULL
a	NULL
role	NULL
for	NULL
PKC	NULL
,	NULL
the	NULL
CaM	NULL
kinases	NULL
,	NULL
casein	NULL
kinases	NULL
I	NULL
,	NULL
II	NULL
and	NULL
IV	NULL
in	NULL
vivo	NULL
.	NULL
``	NULL

Interestingly	NULL
,	NULL
inhibition	NULL
of	NULL
the	NULL
PKC	NULL
pathway	NULL
with	NULL
calphostin	NULL
C	NULL
modestly	NULL
increased	NULL
the	NULL
level	NULL
of	NULL
P-CREB	NULL
detected	NULL
.	NULL

Whether	NULL
this	NULL
was	NULL
a	NULL
result	NULL
of	NULL
increased	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
or	NULL
decreased	NULL
PP1/PP2A-mediated	NULL
dephosphorylation	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL
``	NULL

Inhibition	NULL
of	NULL
the	NULL
CaM	NULL
kinase	NULL
pathway	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
P-CREB	NULL
following	NULL
CD2	NULL
cross-linking	NULL
in	NULL
our	NULL
system	NULL
.	NULL

However	NULL
,	NULL
we	NULL
have	NULL
not	NULL
eliminated	NULL
involvement	NULL
of	NULL
other	NULL
protein	NULL
kinase	NULL
pathways	NULL
in	NULL
the	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
following	NULL
CD2	NULL
signalling	NULL
.	NULL

We	NULL
did	NULL
not	NULL
observe	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
within	NULL
1	NULL
hr	NULL
of	NULL
CD3	NULL
cross-linking	NULL
of	NULL
primary	NULL
human	NULL
PBMC	NULL
unless	NULL
a	NULL
costimulatory	NULL
signal	NULL
from	NULL
exogenous	NULL
IL-2	NULL
was	NULL
supplied	NULL
.	NULL

``	NULL
*	NULL
Previous	NULL
studies	NULL
demonstrating	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
following	NULL
CD3	NULL
cross-linking	NULL
used	NULL
model	NULL
systems	NULL
with	NULL
costimulatory	NULL
signals	NULL
such	NULL
as	NULL
murine	NULL
lymphocytes	NULL
at	NULL
G1	NULL
or	NULL
S	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
©1998	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
95	NULL
,	NULL
544-552	NULL
CD2	NULL
signalling	NULL
induces	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
cycle	NULL
``	NULL
or	NULL
in	NULL
the	NULL
preactivated	NULL
IL-2-independent	NULL
transformed	NULL
Jurkat	NULL
cell	NULL
line	NULL
.	NULL

'*	NULL
Both	NULL
CD2	NULL
and	NULL
CD3	NULL
cross-linking	NULL
increased	NULL
binding	NULL
of	NULL
CREB	NULL
protein	NULL
to	NULL
a	NULL
specific	NULL
radiolabelled	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
suggesting	NULL
that	NULL
binding	NULL
of	NULL
CREB	NULL
to	NULL
DNA	NULL
is	NULL
not	NULL
related	NULL
directly	NULL
to	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
.	NULL

As	NULL
both	NULL
Wollberg	NULL
et	NULL
al	NULL
.	NULL
'	NULL

''	NULL
and	NULL
Nichols	NULL
et	NULL
al	NULL
.	NULL
``	NULL

''	NULL
suggest	NULL
binding	NULL
is	NULL
phosphorylation	NULL
dependent	NULL
,	NULL
phosphorylation	NULL
at	NULL
other	NULL
sites	NULL
may	NULL
modulate	NULL
DNA	NULL
binding	NULL
.	NULL

Alternatively	NULL
,	NULL
activation	NULL
signals	NULL
common	NULL
to	NULL
both	NULL
CD2	NULL
and	NULL
CD3	NULL
signalling	NULL
may	NULL
mediate	NULL
binding	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
to	NULL
DNA	NULL
by	NULL
recruiting	NULL
other	NULL
proteins	NULL
which	NULL
enhance	NULL
or	NULL
stabilize	NULL
DNA	NULL
binding	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
results	NULL
demonstrate	NULL
activation	NULL
of	NULL
the	NULL
cAMP	NULL
second	NULL
messenger	NULL
system	NULL
following	NULL
CD2	NULL
signalling	NULL
and	NULL
enhance	NULL
our	NULL
understanding	NULL
of	NULL
this	NULL
pathway	NULL
by	NULL
demonstrating	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
and	NULL
PKA-dependent	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
in	NULL
primary	NULL
human	NULL
PBMC	NULL
.	NULL

Specific	NULL
modulation	NULL
of	NULL
the	NULL
CREB/ATF-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
by	NULL
the	NULL
CD2	NULL
signalling	NULL
pathway	NULL
suggests	NULL
the	NULL
CD2	NULL
receptor	NULL
may	NULL
be	NULL
important	NULL
in	NULL
CRE-mediated	NULL
transcription	NULL
following	NULL
cell-cell	NULL
contact	NULL
,	NULL
and	NULL
has	NULL
important	NULL
implications	NULL
for	NULL
transcription	NULL
of	NULL
genes	NULL
containing	NULL
CRE	NULL
related	NULL
sequences	NULL
,	NULL
such	NULL
as	NULL
HTLV-1	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
,	NULL
in	NULL
part	NULL
,	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
United	NULL
States	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
AIO1111	NULL
,	NULL
AI01474	NULL
,	NULL
and	NULL
CA55185	NULL
)	NULL
.	NULL

We	NULL
wish	NULL
to	NULL
thank	NULL
Tim	NULL
Vogt	NULL
for	NULL
his	NULL
assistance	NULL
in	NULL
preparation	NULL
of	NULL
illus-trations	NULL
,	NULL
Barbara	NULL
Booth	NULL
and	NULL
Jennifer	NULL
Beard	NULL
for	NULL
technical	NULL
assistance	NULL
,	NULL
and	NULL
Nathaniel	NULL
Collins	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Roster	NULL
W.J	NULL
.	NULL

,	NULL
VanipenBark	NULL
G.R	NULL
.	NULL

&	NULL
Hanson	NULL
RW	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Cyclic	NULL
AMP	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
eukaryotic	NULL
gene	NULL
transcription	NULL
.	NULL

J	NULL
Bio/	NULL
Chem	NULL
263	NULL
,	NULL
9063	NULL
.	NULL

2	NULL
.	NULL

Montminy	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Transcriptional	NULL
regulation	NULL
by	NULL
cyclic	NULL
AMP	NULL
.	NULL

Annu	NULL
Rev	NULL
Biochem	NULL
66	NULL
,	NULL
807	NULL
.	NULL

3	NULL
.	NULL

Kwox	NULL
RP	NULL
.	NULL

,	NULL
LunpsLap	NULL
S.J.R	NULL
.	NULL

,	NULL
Curivia	NULL
J.C.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Nuclear	NULL
protein	NULL
CBP	NULL
is	NULL
a	NULL
co-activator	NULL
for	NULL
the	NULL
transcription	NULL
factor	NULL
CREB	NULL
.	NULL

Nature	NULL
370	NULL
,	NULL
223	NULL
.	NULL

4	NULL
.	NULL

Guvor	NULL
D.J	NULL
.	NULL

,	NULL
Newsounp	NULL
G.C	NULL
.	NULL

&	NULL
Lairmore	NULL
M.D	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Signaling	NULL
via	NULL
the	NULL
CD2	NULL
receptor	NULL
enhances	NULL
HTLV-1	NULL
replication	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Virology	NULL
234	NULL
,	NULL
123	NULL
.	NULL

5	NULL
.	NULL

Francuint	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Molecular	NULL
mechanisms	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia/lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
.	NULL

Blood	NULL
86	NULL
,	NULL
3619	NULL
.	NULL

6	NULL
.	NULL

Kwok	NULL
RP	NULL
.	NULL

,	NULL
Laurance	NULL
ME	NULL
.	NULL

,	NULL
LunpBLap	NULL
S.J.R	NULL
.	NULL

er	NULL
al	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Control	NULL
of	NULL
cAMP	NULL
regulated	NULL
enhancers	NULL
by	NULL
the	NULL
viral	NULL
trans-activator	NULL
Tax	NULL
through	NULL
CREB	NULL
and	NULL
the	NULL
coactivator	NULL
CBP	NULL
.	NULL

Nature	NULL
380	NULL
,	NULL
642	NULL
.	NULL

7	NULL
.	NULL

Laurance	NULL
ME	NULL
.	NULL

,	NULL
Kwok	NULL
RP	NULL
.	NULL

,	NULL
Haung	NULL
M.S	NULL
.	NULL

,	NULL
RicHarps	NULL
J.P.	NULL
,	NULL
LunpBLAD	NULL
J.R.	NULL
&	NULL
GoopmaN	NULL
R.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Differential	NULL
activation	NULL
of	NULL
viral	NULL
and	NULL
cellular	NULL
promoters	NULL
by	NULL
HTLV-1	NULL
Tax	NULL
and	NULL
CREM	NULL
isoforms	NULL
.	NULL

J	NULL
Bio	NULL
!	NULL

Chem	NULL
272	NULL
,	NULL
2646	NULL
.	NULL

8	NULL
.	NULL

Poteat	NULL
HT	NULL
.	NULL

,	NULL
U.	NULL
,	NULL
Yoon	NULL
S.	NULL
,	NULL
Darpik	NULL
M.	NULL
,	NULL
TerwilLiGEr	NULL
E.	NULL
&	NULL
Soproskt	NULL
J.G	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Cyclic	NULL
AMP	NULL
mediated	NULL
growth	NULL
arrest	NULL
is	NULL
associated	NULL
with	NULL
increased	NULL
expression	NULL
of	NULL
HTLV-1	NULL
structural	NULL
and	NULL
transforming	NULL
genes	NULL
.	NULL

AIDS	NULL
Res	NULL
Human	NULL
Retrov	NULL
12	NULL
,	NULL
527	NULL
.	NULL

9	NULL
.	NULL

Haun	NULL
W.C.	NULL
,	NULL
Rosenstein	NULL
Y.	NULL
,	NULL
Burakorr	NULL
S.J	NULL
.	NULL

&	NULL
Bierer	NULL
J.B.	NULL
(	NULL
1991	NULL
)	NULL
Interaction	NULL
of	NULL
CD2	NULL
with	NULL
its	NULL
ligand	NULL
LFA-3	NULL
induces	NULL
cAMP	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Immunol	NULL
147	NULL
,	NULL
14	NULL
.	NULL

10	NULL
.	NULL

Jornson	NULL
K.W	NULL
.	NULL

,	NULL
Davis	NULL
B.W	NULL
.	NULL

&	NULL
Surth	NULL
K.A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
cAMP	NULL
antagonizes	NULL
IL-2	NULL
promoted	NULL
T	NULL
cell	NULL
cycle	NULL
progression	NULL
at	NULL
a	NULL
discrete	NULL
point	NULL
in	NULL
early	NULL
GO	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
85	NULL
,	NULL
6072	NULL
.	NULL

©1998	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
95	NULL
,	NULL
544-552	NULL
11	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

551	NULL
PaLioGtaNnNt	NULL
F.	NULL
,	NULL
KincaiD	NULL
RL	NULL
.	NULL

&	NULL
Boumras	NULL
D.T	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Prostaglandin	NULL
E2	NULL
and	NULL
other	NULL
cAMP	NULL
elevating	NULL
agents	NULL
inhibit	NULL
IL-2	NULL
gene	NULL
transcription	NULL
by	NULL
counteracting	NULL
calcineurin-dependent	NULL
pathways	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
178	NULL
,	NULL
1813.	NULL
.	NULL

HseunH	NULL
Y.P	NULL
.	NULL

&	NULL
Lar	NULL
M.Z	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
c-Jun	NULL
N-terminal	NULL
kinase	NULL
but	NULL
not	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
is	NULL
sensitive	NULL
to	NULL
cAMP	NULL
inhibition	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Bio/	NULL
Chem	NULL
270	NULL
,	NULL
18094.	NULL
.	NULL

Bopor	NULL
J.	NULL
,	NULL
Spetz	NULL
A.L	NULL
.	NULL

,	NULL
StRomingeRr	NULL
J.L	NULL
.	NULL

&	NULL
Hasener	NULL
J.F	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

CyclicAMP	NULL
inducibility	NULL
of	NULL
transcriptional	NULL
repressor	NULL
ICER	NULL
in	NULL
developing	NULL
and	NULL
mature	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
93	NULL
,	NULL
3536	NULL
.	NULL

Kvaxnta	NULL
A.	NULL
,	NULL
Jonoar	NULL
M.	NULL
&	NULL
FrepHiotm	NULL
B.B	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
CD3-dependent	NULL
increase	NULL
in	NULL
cAMP	NULL
following	NULL
stimulation	NULL
of	NULL
the	NULL
CD2	NULL
receptor	NULL
.	NULL

Biochim	NULL
Biophys	NULL
Acta	NULL
1093	NULL
,	NULL
178	NULL
.	NULL

B.S	NULL
.	NULL

,	NULL
Tasken	NULL
K.	NULL
,	NULL
Hansson	NULL
V.	NULL
,	NULL
Huitretor	NULL
HS	NULL
.	NULL

,	NULL
Jannsen	NULL
T.	NULL
&	NULL
Lea	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Location	NULL
of	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
type	NULL
I	NULL
with	NULL
the	NULL
TCR/CD3	NULL
complex	NULL
.	NULL

Science	NULL
263	NULL
,	NULL
84.	NULL
.	NULL

WorrseErg	NULL
P.	NULL
,	NULL
Soperqvist	NULL
H.	NULL
&	NULL
B.D	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Mitogen	NULL
activation	NULL
of	NULL
human	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
induces	NULL
the	NULL
formation	NULL
of	NULL
new	NULL
cAMP	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
nuclear	NULL
complexes	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269	NULL
,	NULL
19719.	NULL
.	NULL

Feversten	NULL
N.	NULL
,	NULL
R.	NULL
,	NULL
Avar	NULL
N.	NULL
,	NULL
Hs	NULL
X.	NULL
,	NULL
Murasko	NULL
D.	NULL
&	NULL
CristoraLo	NULL
V.	NULL
(	NULL
1996	NULL
)	NULL
Late	NULL
induction	NULL
of	NULL
CREB/ATF	NULL
binding	NULL
and	NULL
a	NULL
concomitant	NULL
increase	NULL
in	NULL
cAMP	NULL
levels	NULL
in	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
stimulated	NULL
via	NULL
the	NULL
antigen	NULL
receptor	NULL
.	NULL

J	NULL
Immunol	NULL
156	NULL
,	NULL
4582.	NULL
.	NULL

Brinoue	NULL
P.	NULL
,	NULL
Nakama	NULL
T.	NULL
&	NULL
Montminy	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Multiple	NULL
protein	NULL
kinase	NULL
A-regulated	NULL
events	NULL
are	NULL
required	NULL
for	NULL
transcriptional	NULL
induction	NULL
by	NULL
cAMP	NULL
.	NULL

Proc	NULL
Nat	NULL
!	NULL

Acad	NULL
Sci	NULL
USA	NULL
92	NULL
,	NULL
10521.	NULL
.	NULL

Laxminarayanna	NULL
D.	NULL
&	NULL
Kammer	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
Activation	NULL
of	NULL
type	NULL
1	NULL
PKA	NULL
during	NULL
receptor-mediated	NULL
human	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

J	NULL
Immunol	NULL
156	NULL
,	NULL
497	NULL
.	NULL

Howarp	NULL
F.D	NULL
.	NULL

,	NULL
Monaron	NULL
P.	NULL
,	NULL
Morsius	NULL
U.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
The	NULL
CD3	NULL
{	NULL
cytoplasmic	NULL
domain	NULL
mediates	NULL
CD2-induced	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
176	NULL
,	NULL
139	NULL
.	NULL

Kanner	NULL
$	NULL
.B	NULL
.	NULL

,	NULL
Damue	NULL
N.K	NULL
.	NULL

,	NULL
Brake	NULL
J.	NULL
,	NULL
Arurro	NULL
A	NULL
.	NULL

&	NULL
Lepserrer	NULL
J.A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
CD2/LFA-3	NULL
ligation	NULL
induces	NULL
PLCyl	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
regulates	NULL
CD3	NULL
signaling	NULL
.	NULL

J	NULL
Immunol	NULL
!	NULL

148	NULL
,	NULL
2023	NULL
.	NULL

Husert	NULL
P.	NULL
,	NULL
Lang	NULL
V.	NULL
,	NULL
Desre	NULL
P.	NULL
&	NULL
BismutH	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
Tyrosine	NULL
phosphorylation	NULL
and	NULL
recruitment	NULL
of	NULL
ZAP-70	NULL
to	NULL
the	NULL
CD3-TCR	NULL
complex	NULL
are	NULL
defective	NULL
after	NULL
CD2	NULL
stimulation	NULL
.	NULL

J	NULL
/mmunol	NULL
157	NULL
,	NULL
4322	NULL
.	NULL

NEwsBounp	NULL
G.C	NULL
.	NULL

,	NULL
Anorews	NULL
J.A	NULL
.	NULL

,	NULL
O'Rourke	NULL
J.P.	NULL
,	NULL
Brapy	NULL
J.N	NULL
.	NULL

&	NULL
Lairmore	NULL
M.D	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
tax	NULL
mediates	NULL
enhanced	NULL
transcription	NULL
in	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Virol	NULL
70	NULL
,	NULL
2101	NULL
.	NULL

Guvor	NULL
D.J	NULL
.	NULL

,	NULL
Trask	NULL
O.J	NULL
.	NULL

,	NULL
Anprews	NULL
J.M	NULL
.	NULL

,	NULL
Newsounp	NULL
G.C	NULL
.	NULL

&	NULL
Lairmore	NULL
M.D	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
CD2	NULL
receptor	NULL
pathway	NULL
induces	NULL
apoptosis	NULL
in	NULL
human	NULL
T	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1-infected	NULL
cell	NULL
line	NULL
.	NULL

J	NULL
AIDS	NULL
Human	NULL
Retrov	NULL
11	NULL
,	NULL
317	NULL
.	NULL

June	NULL
CH	NULL
.	NULL

,	NULL
Fretcnuer	NULL
MC	NULL
.	NULL

,	NULL
Leometter	NULL
JA	NULL
.	NULL

et	NULL
al	NULL
(	NULL
1990	NULL
)	NULL
Inhibition	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
prevents	NULL
T-cell	NULL
receptor-mediated	NULL
signal	NULL
transduction	NULL
.	NULL

Proc	NULL
Nat	NULL
!	NULL

Acad	NULL
Sci	NULL
USA	NULL
87	NULL
,	NULL
7722	NULL
.	NULL

GorarakrisHna	NULL
R.	NULL
,	NULL
Curn	NULL
ZH	NULL
.	NULL

&	NULL
Gunopmepa	NULL
U	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Irreversible	NULL
oxidative	NULL
inactivation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
by	NULL
photosensitive	NULL
inhibitor	NULL
,	NULL
calphostin	NULL
C.	NULL
FEBS	NULL
Lett	NULL
314	NULL
,	NULL
149	NULL
.	NULL

Ornes	NULL
M.	NULL
&	NULL
Kurt	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Isolation	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
fragile	NULL
cells	NULL
:	NULL
a	NULL
simplified	NULL
procedure	NULL
applied	NULL
to	NULL
thymocytes	NULL
.	NULL

Biotechniques	NULL
17	NULL
,	NULL
828	NULL
.	NULL

FeUuERsTEIN	NULL
N.	NULL
,	NULL
Huang	NULL
D.	NULL
,	NULL
HenricHs	NULL
S.H	NULL
.	NULL

,	NULL
Orten	NULL
DJ	NULL
.	NULL

,	NULL
Avar	NULL
N.	NULL
&	NULL
Prvrowsky	NULL
M.B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Regulation	NULL
of	NULL
cAMP-responsive	NULL
enhancer	NULL
binding	NULL
proteins	NULL
during	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
by	NULL
IL-2	NULL
.	NULL

J	NULL
Immunol	NULL
!	NULL

153	NULL
,	NULL
68	NULL
.	NULL

MariE-CarRDINE	NULL
A.	NULL
,	NULL
MARIDONNEAU-PARINLI	NULL
I.	NULL
,	NULL
S.	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
The	NULL
lymphocyte-specific	NULL
tyrosine	NULL
kinase	NULL
p56**	NULL
is	NULL
endo-cytosed	NULL
in	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
via	NULL
CD2	NULL
.	NULL

J	NULL
/mmunol	NULL
148	NULL
,	NULL
3879	NULL
.	NULL

HuonEs	NULL
C.W	NULL
.	NULL

&	NULL
Poser	NULL
J.S	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
in	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Bio/	NULL
Chem	NULL
271	NULL
,	NULL
5369	NULL
.	NULL

552	NULL
3	NULL
3	NULL
ta	NULL
ue	NULL
1	NULL
.	NULL

2	NULL
.	NULL

King	NULL
P.D	NULL
.	NULL

,	NULL
Sapra	NULL
A.	NULL
,	NULL
Han	NULL
A.	NULL
,	NULL
Liv	NULL
X.-R.	NULL
,	NULL
R.	NULL
,	NULL
Ruinnerz	NULL
EL	NULL
.	NULL

&	NULL
Duront	NULL
B	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
CD2	NULL
signaling	NULL
in	NULL
T	NULL
cells	NULL
involves	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
Tec	NULL
family	NULL
kinase	NULL
EMT/ITK/TSK	NULL
.	NULL

Int/	NULL
Immunol	NULL
8	NULL
,	NULL
1707	NULL
.	NULL

TANAKA	NULL
N.	NULL
,	NULL
Ass	NULL
H.	NULL
,	NULL
Yaorra	NULL
H.	NULL
,	NULL
Oxumura	NULL
K.	NULL
,	NULL
Nakamura	NULL
N.	NULL
&	NULL
Sugamura	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
ITK	NULL
,	NULL
a	NULL
T	NULL
cell	NULL
specific	NULL
tyrosine	NULL
kinase	NULL
is	NULL
required	NULL
for	NULL
CD2-mediated	NULL
IL-2	NULL
promoter	NULL
activation	NULL
in	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
line	NULL
Jurkat	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
27	NULL
,	NULL
4.	NULL
.	NULL

AuBERTS	NULL
A.S.	NULL
,	NULL
Montuiny	NULL
M.	NULL
,	NULL
Surnoumar	NULL
S.	NULL
&	NULL
FrrRamisco	NULL
J.R.	NULL
(	NULL
1994	NULL
)	NULL
Expression	NULL
of	NULL
a	NULL
peptide	NULL
inhibitor	NULL
of	NULL
protein	NULL
phosphatase	NULL
35	NULL
.	NULL

D.	NULL
J.	NULL
Guyot	NULL
et	NULL
al	NULL
.	NULL

1	NULL
increases	NULL
phosphorylation	NULL
and	NULL
activity	NULL
of	NULL
CREB	NULL
in	NULL
NIH	NULL
3T3	NULL
fibroblasts	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14	NULL
,	NULL
4398.	NULL
.	NULL

Guvor	NULL
D.J	NULL
.	NULL

,	NULL
Newsounp	NULL
G.C	NULL
.	NULL

&	NULL
Lairmore	NULL
M.D	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Co	NULL
stimulation	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
with	NULL
IL-2	NULL
and	NULL
anti-CD3	NULL
monoclonal	NULL
antibodies	NULL
induces	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

Immunol	NULL
Lett	NULL
61	NULL
,	NULL
45	NULL
.	NULL

Nictrors	NULL
M.	NULL
,	NULL
Wein	NULL
F.	NULL
,	NULL
Scrmin	NULL
W.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Phosphorylation	NULL
of	NULL
CREB	NULL
affects	NULL
its	NULL
binding	NULL
to	NULL
high	NULL
and	NULL
low	NULL
affinity	NULL
sites	NULL
:	NULL
implications	NULL
for	NULL
cAMP-induced	NULL
gene	NULL
expression	NULL
.	NULL

EMBO	NULL
J	NULL
11	NULL
,	NULL
3337	NULL
.	NULL

©	NULL
1998	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
95	NULL
,	NULL
544	NULL
552	NULL

